<!DOCTYPE html><html lang="zh-TW"><head><title>Early-Stage Triple-Negative Breast Cancer Journey</title><meta property="og:title" content="Early-Stage Triple-Negative Breast Cancer Journey"><meta name="author" content="Hsieh-Ting Lin"><meta property="article:author" content="Hsieh-Ting Lin"><meta charset="UTF-8"><meta name="viewport" content="width=device-width,height=device-height,initial-scale=1.0"><meta name="apple-mobile-web-app-capable" content="yes"><meta http-equiv="X-UA-Compatible" content="ie=edge"><meta property="og:type" content="website"><meta name="twitter:card" content="summary"><style>@media screen{body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button,body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button,body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container button,body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container button{-webkit-tap-highlight-color:transparent;appearance:none;background-color:transparent;border:0;color:inherit;cursor:pointer;font-size:inherit;opacity:.8;outline:none;padding:0;transition:opacity .2s linear}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button:disabled,body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button:disabled,body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container button:disabled,body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container button:disabled{cursor:not-allowed;opacity:.15!important}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button:hover,body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button:hover,body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container button:hover,body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container button:hover{opacity:1}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button:hover:active,body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button:hover:active,body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container button:hover:active,body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container button:hover:active{opacity:.6}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button:hover:not(:disabled),body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button:hover:not(:disabled),body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container button:hover:not(:disabled),body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container button:hover:not(:disabled){transition:none}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=prev],body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=prev],body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container button.bespoke-marp-presenter-info-page-prev{background:transparent url("data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgMCAxMDAgMTAwIj48cGF0aCBmaWxsPSJub25lIiBzdHJva2U9IiNmZmYiIHN0cm9rZS1saW5lY2FwPSJyb3VuZCIgc3Ryb2tlLWxpbmVqb2luPSJyb3VuZCIgc3Ryb2tlLXdpZHRoPSI1IiBkPSJNNjggOTAgMjggNTBsNDAtNDAiLz48L3N2Zz4=") no-repeat 50%;background-size:contain;overflow:hidden;text-indent:100%;white-space:nowrap}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=next],body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=next],body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container button.bespoke-marp-presenter-info-page-next{background:transparent url("data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgMCAxMDAgMTAwIj48cGF0aCBmaWxsPSJub25lIiBzdHJva2U9IiNmZmYiIHN0cm9rZS1saW5lY2FwPSJyb3VuZCIgc3Ryb2tlLWxpbmVqb2luPSJyb3VuZCIgc3Ryb2tlLXdpZHRoPSI1IiBkPSJtMzIgOTAgNDAtNDAtNDAtNDAiLz48L3N2Zz4=") no-repeat 50%;background-size:contain;overflow:hidden;text-indent:100%;white-space:nowrap}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=fullscreen],body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=fullscreen]{background:transparent url("data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgMCAxMDAgMTAwIj48ZGVmcz48c3R5bGU+LmF7ZmlsbDpub25lO3N0cm9rZTojZmZmO3N0cm9rZS1saW5lY2FwOnJvdW5kO3N0cm9rZS1saW5lam9pbjpyb3VuZDtzdHJva2Utd2lkdGg6NXB4fTwvc3R5bGU+PC9kZWZzPjxyZWN0IHdpZHRoPSI4MCIgaGVpZ2h0PSI2MCIgeD0iMTAiIHk9IjIwIiBjbGFzcz0iYSIgcng9IjUuNjciLz48cGF0aCBkPSJNNDAgNzBIMjBWNTBtMjAgMEwyMCA3MG00MC00MGgyMHYyMG0tMjAgMCAyMC0yMCIgY2xhc3M9ImEiLz48L3N2Zz4=") no-repeat 50%;background-size:contain;overflow:hidden;text-indent:100%;white-space:nowrap}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button.exit[data-bespoke-marp-osc=fullscreen],body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button.exit[data-bespoke-marp-osc=fullscreen]{background-image:url("data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgMCAxMDAgMTAwIj48ZGVmcz48c3R5bGU+LmF7ZmlsbDpub25lO3N0cm9rZTojZmZmO3N0cm9rZS1saW5lY2FwOnJvdW5kO3N0cm9rZS1saW5lam9pbjpyb3VuZDtzdHJva2Utd2lkdGg6NXB4fTwvc3R5bGU+PC9kZWZzPjxyZWN0IHdpZHRoPSI4MCIgaGVpZ2h0PSI2MCIgeD0iMTAiIHk9IjIwIiBjbGFzcz0iYSIgcng9IjUuNjciLz48cGF0aCBkPSJNMjAgNTBoMjB2MjBtLTIwIDAgMjAtMjBtNDAgMEg2MFYzMG0yMCAwTDYwIDUwIiBjbGFzcz0iYSIvPjwvc3ZnPg==")}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=presenter],body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=presenter]{background:transparent url("data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgMCAxMDAgMTAwIj48cGF0aCBmaWxsPSJub25lIiBzdHJva2U9IiNmZmYiIHN0cm9rZS1saW5lY2FwPSJyb3VuZCIgc3Ryb2tlLWxpbmVqb2luPSJyb3VuZCIgc3Ryb2tlLXdpZHRoPSI1IiBkPSJNODcuOCA0Ny41Qzg5IDUwIDg3LjcgNTIgODUgNTJIMzVhOC43IDguNyAwIDAgMS03LjItNC41bC0xNS42LTMxQzExIDE0IDEyLjIgMTIgMTUgMTJoNTBhOC44IDguOCAwIDAgMSA3LjIgNC41ek02MCA1MnYzNm0tMTAgMGgyME00NSA0MmgyMCIvPjwvc3ZnPg==") no-repeat 50%;background-size:contain;overflow:hidden;text-indent:100%;white-space:nowrap}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container button.bespoke-marp-presenter-note-bigger{background:transparent url("data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgMCAxMDAgMTAwIj48cGF0aCBzdHJva2U9IiNmZmYiIHN0cm9rZS1saW5lY2FwPSJyb3VuZCIgc3Ryb2tlLWxpbmVqb2luPSJyb3VuZCIgc3Ryb2tlLXdpZHRoPSI1IiBkPSJNMTIgNTBoODBNNTIgOTBWMTAiLz48L3N2Zz4=") no-repeat 50%;background-size:contain;overflow:hidden;text-indent:100%;white-space:nowrap}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container button.bespoke-marp-presenter-note-smaller{background:transparent url("data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgMCAxMDAgMTAwIj48cGF0aCBmaWxsPSJub25lIiBzdHJva2U9IiNmZmYiIHN0cm9rZS1saW5lY2FwPSJyb3VuZCIgc3Ryb2tlLWxpbmVqb2luPSJyb3VuZCIgc3Ryb2tlLXdpZHRoPSI1IiBkPSJNMTIgNTBoODAiLz48L3N2Zz4=") no-repeat 50%;background-size:contain;overflow:hidden;text-indent:100%;white-space:nowrap}}@keyframes __bespoke_marp_transition_reduced_outgoing__{0%{opacity:1}to{opacity:0}}@keyframes __bespoke_marp_transition_reduced_incoming__{0%{mix-blend-mode:plus-lighter;opacity:0}to{mix-blend-mode:plus-lighter;opacity:1}}.bespoke-marp-note,.bespoke-marp-osc,.bespoke-progress-parent{display:none;transition:none}@media screen{::view-transition-group(*){animation-duration:var(--marp-bespoke-transition-animation-duration,.5s);animation-timing-function:ease}::view-transition-new(*),::view-transition-old(*){animation-delay:0s;animation-direction:var(--marp-bespoke-transition-animation-direction,normal);animation-duration:var(--marp-bespoke-transition-animation-duration,.5s);animation-fill-mode:both;animation-name:var(--marp-bespoke-transition-animation-name,var(--marp-bespoke-transition-animation-name-fallback,__bespoke_marp_transition_no_animation__));mix-blend-mode:normal}::view-transition-old(*){--marp-bespoke-transition-animation-name-fallback:__bespoke_marp_transition_reduced_outgoing__;animation-timing-function:ease}::view-transition-new(*){--marp-bespoke-transition-animation-name-fallback:__bespoke_marp_transition_reduced_incoming__;animation-timing-function:ease}::view-transition-new(root),::view-transition-old(root){animation-timing-function:linear}::view-transition-new(__bespoke_marp_transition_osc__),::view-transition-old(__bespoke_marp_transition_osc__){animation-duration:0s!important;animation-name:__bespoke_marp_transition_osc__!important}::view-transition-new(__bespoke_marp_transition_osc__){opacity:0!important}.bespoke-marp-transition-warming-up::view-transition-group(*),.bespoke-marp-transition-warming-up::view-transition-new(*),.bespoke-marp-transition-warming-up::view-transition-old(*){animation-play-state:paused!important}body,html{height:100%;margin:0}body{background:#000;overflow:hidden}svg.bespoke-marp-slide{content-visibility:hidden;opacity:0;pointer-events:none;z-index:-1}svg.bespoke-marp-slide:not(.bespoke-marp-active) *{view-transition-name:none!important}svg.bespoke-marp-slide.bespoke-marp-active{content-visibility:visible;opacity:1;pointer-events:auto;z-index:0}svg.bespoke-marp-slide.bespoke-marp-active.bespoke-marp-active-ready *{animation-name:__bespoke_marp__!important}@supports not (content-visibility:hidden){svg.bespoke-marp-slide[data-bespoke-marp-load=hideable]{display:none}svg.bespoke-marp-slide[data-bespoke-marp-load=hideable].bespoke-marp-active{display:block}}}@media screen and (prefers-reduced-motion:reduce){svg.bespoke-marp-slide *{view-transition-name:none!important}}@media screen{[data-bespoke-marp-fragment=inactive]{visibility:hidden}body[data-bespoke-view=""] .bespoke-marp-parent,body[data-bespoke-view=next] .bespoke-marp-parent{inset:0;position:absolute}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc,body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc{view-transition-name:__bespoke_marp_transition_osc__;background:rgba(0,0,0,.65);border-radius:7px;bottom:50px;color:#fff;contain:paint;display:block;font-family:Helvetica,Arial,sans-serif;font-size:16px;left:50%;line-height:0;opacity:1;padding:12px;position:absolute;touch-action:manipulation;transform:translateX(-50%);transition:opacity .2s linear;-webkit-user-select:none;user-select:none;white-space:nowrap;will-change:transform;z-index:1}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>*,body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>*{margin-left:6px}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>:first-child,body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>:first-child{margin-left:0}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>span,body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>span{opacity:.8}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>span[data-bespoke-marp-osc=page],body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>span[data-bespoke-marp-osc=page]{display:inline-block;min-width:140px;text-align:center}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=fullscreen],body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=next],body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=presenter],body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=prev],body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=fullscreen],body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=next],body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=presenter],body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=prev]{height:32px;line-height:32px;width:32px}body[data-bespoke-view=""] .bespoke-marp-parent.bespoke-marp-inactive,body[data-bespoke-view=next] .bespoke-marp-parent.bespoke-marp-inactive{cursor:none}body[data-bespoke-view=""] .bespoke-marp-parent.bespoke-marp-inactive>.bespoke-marp-osc,body[data-bespoke-view=next] .bespoke-marp-parent.bespoke-marp-inactive>.bespoke-marp-osc{opacity:0;pointer-events:none}body[data-bespoke-view=""] svg.bespoke-marp-slide,body[data-bespoke-view=next] svg.bespoke-marp-slide{height:100%;left:0;position:absolute;top:0;width:100%}body[data-bespoke-view=""] .bespoke-progress-parent{background:#222;display:flex;height:5px;width:100%}body[data-bespoke-view=""] .bespoke-progress-parent+.bespoke-marp-parent{top:5px}body[data-bespoke-view=""] .bespoke-progress-parent .bespoke-progress-bar{background:#0288d1;flex:0 0 0;transition:flex-basis .2s cubic-bezier(0,1,1,1)}body[data-bespoke-view=next]{background:transparent}body[data-bespoke-view=presenter]{background:#161616}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container{display:grid;font-family:Helvetica,Arial,sans-serif;grid-template:"current dragbar next" minmax(140px,1fr) "current dragbar note" 2fr "info    dragbar note" 3em;grid-template-columns:minmax(3px,var(--bespoke-marp-presenter-split-ratio,66%)) 0 minmax(3px,1fr);height:100%;left:0;position:absolute;top:0;width:100%}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-parent{grid-area:current;overflow:hidden;position:relative}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-parent svg.bespoke-marp-slide{height:calc(100% - 40px);left:20px;pointer-events:none;position:absolute;top:20px;-webkit-user-select:none;user-select:none;width:calc(100% - 40px)}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-parent svg.bespoke-marp-slide.bespoke-marp-active{filter:drop-shadow(0 3px 10px rgba(0,0,0,.5))}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-dragbar-container{background:#0288d1;cursor:col-resize;grid-area:dragbar;margin-left:-3px;opacity:0;position:relative;transition:opacity .4s linear .1s;width:6px;z-index:10}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-dragbar-container:hover{opacity:1}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-dragbar-container.active{opacity:1;transition-delay:0s}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-next-container{background:#222;cursor:pointer;display:none;grid-area:next;overflow:hidden;position:relative}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-next-container.active{display:block}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-next-container iframe.bespoke-marp-presenter-next{background:transparent;border:0;display:block;filter:drop-shadow(0 3px 10px rgba(0,0,0,.5));height:calc(100% - 40px);left:20px;pointer-events:none;position:absolute;top:20px;-webkit-user-select:none;user-select:none;width:calc(100% - 40px)}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container{background:#222;color:#eee;grid-area:note;position:relative;z-index:1}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container button{height:1.5em;line-height:1.5em;width:1.5em}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container .bespoke-marp-presenter-note-wrapper{display:block;inset:0;position:absolute}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container .bespoke-marp-presenter-note-buttons{background:rgba(0,0,0,.65);border-radius:4px;bottom:0;display:flex;gap:4px;margin:12px;opacity:0;padding:6px;pointer-events:none;position:absolute;right:0;transition:opacity .2s linear}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container .bespoke-marp-presenter-note-buttons:focus-within,body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container .bespoke-marp-presenter-note-wrapper:focus-within+.bespoke-marp-presenter-note-buttons,body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container:hover .bespoke-marp-presenter-note-buttons{opacity:1;pointer-events:auto}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container .bespoke-marp-note{word-wrap:break-word;box-sizing:border-box;font-size:calc(1.1em*var(--bespoke-marp-note-font-scale, 1));height:calc(100% - 40px);margin:20px;overflow:auto;padding-right:3px;scrollbar-color:hsla(0,0%,93%,.5) transparent;scrollbar-width:thin;white-space:pre-wrap;width:calc(100% - 40px)}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container .bespoke-marp-note::-webkit-scrollbar{width:6px}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container .bespoke-marp-note::-webkit-scrollbar-track{background:transparent}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container .bespoke-marp-note::-webkit-scrollbar-thumb{background:hsla(0,0%,93%,.5);border-radius:6px}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container .bespoke-marp-note:empty{pointer-events:none}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container .bespoke-marp-note.active{display:block}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container .bespoke-marp-note p:first-child{margin-top:0}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container .bespoke-marp-note p:last-child{margin-bottom:0}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container{align-items:center;box-sizing:border-box;color:#eee;display:flex;flex-wrap:nowrap;grid-area:info;justify-content:center;overflow:hidden;padding:0 10px}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container .bespoke-marp-presenter-info-page,body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container .bespoke-marp-presenter-info-time,body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container .bespoke-marp-presenter-info-timer{box-sizing:border-box;display:block;padding:0 10px;white-space:nowrap;width:100%}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container button{height:1.5em;line-height:1.5em;width:1.5em}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container .bespoke-marp-presenter-info-page{order:2;text-align:center}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container .bespoke-marp-presenter-info-page .bespoke-marp-presenter-info-page-text{display:inline-block;min-width:120px;text-align:center}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container .bespoke-marp-presenter-info-time{color:#999;order:1;text-align:left}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container .bespoke-marp-presenter-info-timer{color:#999;order:3;text-align:right}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container .bespoke-marp-presenter-info-timer:hover{cursor:pointer}}@media print{.bespoke-marp-presenter-info-container,.bespoke-marp-presenter-next-container,.bespoke-marp-presenter-note-container{display:none}}</style><style>@charset "UTF-8";@import url("https://unpkg.com/markdown-it-admon/styles/admonition.css");@import url("https://fonts.googleapis.com/css2?family=Overpass+Mono:wght@400;500;600;700&display=swap");@import url("https://cdn.jsdelivr.net/npm/bootstrap-icons@1.11.2/font/bootstrap-icons.min.css");@import url("https://fonts.googleapis.com/css2?family=JetBrains+Mono:wght@400;600;800&display=swap");@import url("https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700;800&family=JetBrains+Mono:wght@400;600;800&display=swap");@import url("https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200");@import url("https://unpkg.com/boxicons@2.1.4/css/boxicons.min.css");div#\:\$p>svg>foreignObject>section{width:1280px;height:720px;box-sizing:border-box;overflow:hidden;position:relative;scroll-snap-align:center center}div#\:\$p>svg>foreignObject>section:after{bottom:0;content:attr(data-marpit-pagination);padding:inherit;pointer-events:none;position:absolute;right:0}div#\:\$p>svg>foreignObject>section:not([data-marpit-pagination]):after{display:none}/* Normalization */div#\:\$p>svg>foreignObject>section :is(h1,marp-h1){font-size:2em;margin:0.67em 0}div#\:\$p>svg>foreignObject>section video::-webkit-media-controls{will-change:transform}@page{size:1280px 720px;margin:0}@media print{body,html{background-color:#fff;margin:0;page-break-inside:avoid;break-inside:avoid-page}div#\:\$p>svg>foreignObject>section{page-break-before:always;break-before:page}div#\:\$p>svg>foreignObject>section,div#\:\$p>svg>foreignObject>section *{-webkit-print-color-adjust:exact!important;animation-delay:0s!important;animation-duration:0s!important;color-adjust:exact!important;transition:none!important}div#\:\$p>svg[data-marpit-svg]{display:block;height:100vh;width:100vw}}div#\:\$p>svg>foreignObject>:where(section){container-type:size}div#\:\$p>svg>foreignObject>section img[data-marp-twemoji]{background:transparent;height:1em;margin:0 .05em 0 .1em;vertical-align:-.1em;width:1em}

/* @theme my-theme */
/*!
 *
 * @auto-scaling true
 * @size 4:3 960px 720px
 * @size 16:9 1280px 720px
 */
/* @import url("https://fonts.googleapis.com/css2?family=Open+Sans:ital,wght@0,500;0,600;0,700;0,800;1,500;1,600&display=swap"); */
/* @import url("https://fonts.googleapis.com/css2?family=Fira+Sans:ital,wght@0,400;0,500;0,600;0,700;0,800;0,900;1,400;1,500;1,600;1,700;1,800;1,900&display=swap"); */div#\:\$p>svg>foreignObject>:where(section):not([root]){--JAMA-foreground:#333;--JAMA-current-line:#e5e5e5;--JAMA-background:#ffffff;
  /* --JAMA-background: #f8f8f2; */--JAMA-comment:#6272a4;--JAMA-cyan:#192b2f;--JAMA-blue:#2d696a;--JAMA-green:#6c9a77;--JAMA-orange:#841e2f;--JAMA-pink:#9a2f6b;--JAMA-purple:#4f2d7d;--JAMA-red:#d71635;--JAMA-yellow:#8c9434}div#\:\$p>svg>foreignObject>section .hljs{display:block;overflow-x:auto;padding:0.5em;background:#282a36}div#\:\$p>svg>foreignObject>section .hljs-built_in,div#\:\$p>svg>foreignObject>section .hljs-link,div#\:\$p>svg>foreignObject>section .hljs-section,div#\:\$p>svg>foreignObject>section .hljs-selector-tag{color:#8be9fd}div#\:\$p>svg>foreignObject>section .hljs-keyword{color:#ff79c6}div#\:\$p>svg>foreignObject>section .hljs,div#\:\$p>svg>foreignObject>section .hljs-subst{color:#f8f8f2}div#\:\$p>svg>foreignObject>section .hljs-attr,div#\:\$p>svg>foreignObject>section .hljs-meta-keyword,div#\:\$p>svg>foreignObject>section .hljs-title{color:#50fa7b}div#\:\$p>svg>foreignObject>section .hljs-addition,div#\:\$p>svg>foreignObject>section .hljs-bullet,div#\:\$p>svg>foreignObject>section .hljs-meta,div#\:\$p>svg>foreignObject>section .hljs-name,div#\:\$p>svg>foreignObject>section .hljs-string,div#\:\$p>svg>foreignObject>section .hljs-symbol,div#\:\$p>svg>foreignObject>section .hljs-template-tag,div#\:\$p>svg>foreignObject>section .hljs-template-variable,div#\:\$p>svg>foreignObject>section .hljs-type,div#\:\$p>svg>foreignObject>section .hljs-variable{color:#f1fa8c}div#\:\$p>svg>foreignObject>section .hljs-comment,div#\:\$p>svg>foreignObject>section .hljs-deletion,div#\:\$p>svg>foreignObject>section .hljs-quote{color:#6272a4}div#\:\$p>svg>foreignObject>section .hljs-doctag,div#\:\$p>svg>foreignObject>section .hljs-keyword,div#\:\$p>svg>foreignObject>section .hljs-literal,div#\:\$p>svg>foreignObject>section .hljs-name,div#\:\$p>svg>foreignObject>section .hljs-section,div#\:\$p>svg>foreignObject>section .hljs-selector-tag,div#\:\$p>svg>foreignObject>section .hljs-strong,div#\:\$p>svg>foreignObject>section .hljs-title,div#\:\$p>svg>foreignObject>section .hljs-type{font-weight:bold}div#\:\$p>svg>foreignObject>section .hljs-literal,div#\:\$p>svg>foreignObject>section .hljs-number{color:#bd93f9}div#\:\$p>svg>foreignObject>section .hljs-emphasis{font-style:italic}div#\:\$p>svg>foreignObject>section svg[data-marp-fitting=svg]{max-height:580px}div#\:\$p>svg>foreignObject>section :is(h1,marp-h1),div#\:\$p>svg>foreignObject>section :is(h2,marp-h2),div#\:\$p>svg>foreignObject>section :is(h3,marp-h3),div#\:\$p>svg>foreignObject>section :is(h4,marp-h4),div#\:\$p>svg>foreignObject>section :is(h5,marp-h5),div#\:\$p>svg>foreignObject>section :is(h6,marp-h6){margin:0.2em 0 0 0;max-width:1000px;animation-name:fadeIn;animation-duration:0.2s;animation-fill-mode:both;transition:transform 0.2s ease}div#\:\$p>svg>foreignObject>section>:is(h1,marp-h1):hover,div#\:\$p>svg>foreignObject>section>:is(h2,marp-h2):hover,div#\:\$p>svg>foreignObject>section>:is(h3,marp-h3):hover,div#\:\$p>svg>foreignObject>section>:is(h4,marp-h4):hover,div#\:\$p>svg>foreignObject>section>:is(h5,marp-h5):hover{transform:translateX(10px);
  /* transform: scale(1.05); */transition:transform 0.3s ease}div#\:\$p>svg>foreignObject>section :is(h1,marp-h1) strong,div#\:\$p>svg>foreignObject>section :is(h2,marp-h2) strong,div#\:\$p>svg>foreignObject>section :is(h3,marp-h3) strong,div#\:\$p>svg>foreignObject>section :is(h4,marp-h4) strong,div#\:\$p>svg>foreignObject>section :is(h5,marp-h5) strong,div#\:\$p>svg>foreignObject>section :is(h6,marp-h6) strong{font-weight:inherit}div#\:\$p>svg>foreignObject>section li strong{animation-name:fadeIn;animation-duration:1s;animation-fill-mode:both;animation-delay:0.5s;transition:transform 0.3s ease}div#\:\$p>svg>foreignObject>section strong{
  /* font-weight: bold; */font-weight:800;
  /* background-color: var(--JAMA-blue); */
  /* color: var(--JAMA-blue); */
  /* text-decoration: underline; */
  /* text-decoration-color: #6c9a77; */
  /* text-decoration-style: solid; */padding:0px 5px 0px 5px;background:-webkit-linear-gradient(right,#6c9a77,#2d696a);-webkit-background-clip:text;-webkit-text-fill-color:transparent}div#\:\$p>svg>foreignObject>section :is(h1,marp-h1){
  /* TODO: */font-size:3em;font-weight:900;
  /* font-style: italic; */
  /* margin-top: 100px; */margin-bottom:50px;color:var(--JAMA-foreground)}div#\:\$p>svg>foreignObject>section :is(h2,marp-h2){font-size:1.5em;font-weight:900;color:var(--JAMA-blue)}div#\:\$p>svg>foreignObject>section :is(h3,marp-h3){font-size:1.3em;color:var(--JAMA-foreground)}div#\:\$p>svg>foreignObject>section :is(h4,marp-h4){font-size:1.2em;opacity:0.5;color:var(--JAMA-foreground)}div#\:\$p>svg>foreignObject>section :is(h5,marp-h5){font-size:1.1em;color:var(--JAMA-blue)}div#\:\$p>svg>foreignObject>section :is(h6,marp-h6){font-size:1em;color:var(--JAMA-blue)}div#\:\$p>svg>foreignObject>section p{font-size:1em;margin:1em 0 1em 0
  /* transition: 0.3s; */}div#\:\$p>svg>foreignObject>section blockquote{font-size:0.6em;margin:1em 0 0 0;animation-name:fadeIn;animation-duration:1s;animation-fill-mode:both;animation-delay:1.5s}div#\:\$p>svg>foreignObject>section ol>li,div#\:\$p>svg>foreignObject>section ul>li{margin:0.5em 0 0 0;color:var(--JAMA-cyan)}div#\:\$p>svg>foreignObject>section ol>li>p,div#\:\$p>svg>foreignObject>section ul>li>p{margin:0.6em 0 0 0}div#\:\$p>svg>foreignObject>section code{display:inline-block;font-family:"Open Sans",sans-serif;
  /* font-family: "Inter", sans-serif; */
  /* font-family: 'JetBrains Mono', monospace; */font-weight:800;font-size:0.9em;letter-spacing:0.4;margin:0.3em;padding:0.2em 0.4em 0.2em 0.4em;vertical-align:baseline}div#\:\$p>svg>foreignObject>section :is(pre,marp-pre){display:block;min-height:1em;color:#fff;overflow:visible}div#\:\$p>svg>foreignObject>section :is(pre,marp-pre) code{box-sizing:border-box;line-height:1em;background:#333;margin:0;min-width:100%;padding:1em;font-size:1em}div#\:\$p>svg>foreignObject>section :is(pre,marp-pre) code svg[data-marp-fitting=svg]{max-height:calc(480px - 1em)}div#\:\$p>svg>foreignObject>section blockquote{padding-top:5px;border-top:0.1px solid #555;margin-top:10px;font-size:50%;color:var(--JAMA-foreground);background:var(--JAMA-background);position:absolute;bottom:10px;right:80px;left:40px}div#\:\$p>svg>foreignObject>section blockquote:before{content:"";display:block;font-weight:bold;position:absolute;color:var(--JAMA-green);top:0;left:0}div#\:\$p>svg>foreignObject>section blockquote>:first-child{margin-top:0}div#\:\$p>svg>foreignObject>section blockquote>blockquote>blockquote{font-size:50%;font-weight:400;padding:0;margin:0;border:0;border-top:0.1em dashed #555;position:absolute;bottom:-10px;left:10px}div#\:\$p>svg>foreignObject>section mark{background:transparent}div#\:\$p>svg>foreignObject>section table{border-spacing:0;border-collapse:collapse;border-collapse:collapse;border-radius:10px; /* sets the border radius */overflow:hidden; /* hides the overflow from the rounded corners */margin:1em 0 0 0;transition:transform 0.3s ease}div#\:\$p>svg>foreignObject>section table td,div#\:\$p>svg>foreignObject>section table th{padding:0.2em 0.4em;border-width:1px;border-style:solid}div#\:\$p>svg>foreignObject>section table th{background-color:blue; /* sets the background color of the table header */color:white /* sets the text color of the table header to white */}div#\:\$p>svg>foreignObject>section{font-size:26px;font-weight:500;
  /* font-family: "Open Sans", sans-serif; */font-family:"Inter",sans-serif;
  /* font-family: "Fira Sans", sans-serif; */
  /* TODO: Change Main Font Here */line-height:1.15;
  /* letter-spacing: 0.4px; */padding:50px 35px;color:var(--JAMA-foreground);background-color:var(--JAMA-background);border-left:15px solid;border-image:linear-gradient(to bottom,#6c9a77,#2d696a);border-image-slice:1}div#\:\$p>svg>foreignObject>section{--marpit-root-font-size:26px}div#\:\$p>svg>foreignObject>section>:first-child,div#\:\$p>svg>foreignObject>section>header:first-child+*{margin-top:0}div#\:\$p>svg>foreignObject>section a,div#\:\$p>svg>foreignObject>section mark{color:var(--JAMA-red)}div#\:\$p>svg>foreignObject>section code{
  /* background: var(--JAMA-blue); */border-radius:0.8em;border:2px solid var(--JAMA-blue);color:var(--JAMA-blue);animation-name:fadeIn;animation-duration:0.5s;animation-fill-mode:both;animation-delay:0.2s}div#\:\$p>svg>foreignObject>section :is(h1,marp-h1) strong,div#\:\$p>svg>foreignObject>section :is(h2,marp-h2) strong,div#\:\$p>svg>foreignObject>section :is(h3,marp-h3) strong,div#\:\$p>svg>foreignObject>section :is(h4,marp-h4) strong,div#\:\$p>svg>foreignObject>section :is(h5,marp-h5) strong,div#\:\$p>svg>foreignObject>section :is(h6,marp-h6) strong{background:-webkit-linear-gradient(right,#6c9a77,#2d696a);-webkit-background-clip:text;-webkit-text-fill-color:transparent}div#\:\$p>svg>foreignObject>section :is(h4,marp-h4),div#\:\$p>svg>foreignObject>section header{opacity:0;transform:translateY(-40px);animation:fade-in 0.5s cubic-bezier(0.4,0,0.2,1) forwards}div#\:\$p>svg>foreignObject>section>p{transition:transform 0.2s ease}div#\:\$p>svg>foreignObject>section blockquote:after,div#\:\$p>svg>foreignObject>section blockquote:before,div#\:\$p>svg>foreignObject>section footer,div#\:\$p>svg>foreignObject>section header,div#\:\$p>svg>foreignObject>section section:after{color:var(--JAMA-comment)}div#\:\$p>svg>foreignObject>section table td,div#\:\$p>svg>foreignObject>section table th{border-color:var(--JAMA-current-line);font-size:0.8em}div#\:\$p>svg>foreignObject>section table thead th{background:var(--JAMA-foreground);color:var(--JAMA-background);font-size:0.8em}div#\:\$p>svg>foreignObject>section table tbody>tr:nth-child(2n) td,div#\:\$p>svg>foreignObject>section table tbody>tr:nth-child(2n) th{background:var(--JAMA-current-line);font-size:0.8em}div#\:\$p>svg>foreignObject>section footer,div#\:\$p>svg>foreignObject>section header,div#\:\$p>svg>foreignObject>section:after{box-sizing:border-box;font-size:66%;line-height:30px;
  /* overflow: hidden; */padding:35px 35px;position:absolute;color:var(--JAMA-blue)}div#\:\$p>svg>foreignObject>section:after{--marpit-root-font-size:66%}div#\:\$p>svg>foreignObject>section:after{animation-name:slideInRight;animation-duration:1s;animation-fill-mode:both;animation-timing-function:cubic-bezier(0.6,0.05,0.4,0.95)}div#\:\$p>svg>foreignObject>section header{background-color:#2d696a;
  /* background: linear-gradient(to left, #2d696a, #6c9a77); */color:#ffffff;border-bottom-left-radius:15px;
  /* border-bottom-right-radius: 15px; */
  /* border-left: #2d696a 35px solid; */height:43px;padding-top:5px;right:0;top:0;font-weight:700;text-align:right;max-width:500px}div#\:\$p>svg>foreignObject>section .today{}div#\:\$p>svg>foreignObject>section footer{left:0;right:0;bottom:0}div#\:\$p>svg>foreignObject>section:after{right:0;bottom:0;font-size:80%}div#\:\$p>svg>foreignObject>section:after{--marpit-root-font-size:80%}div#\:\$p>svg>foreignObject>section .free{display:flex;width:100%;gap:calc(var(--marpit-root-font-size, 1rem) * 1.5)}div#\:\$p>svg>foreignObject>section .free div{display:flex;flex-direction:column;justify-content:center
  /* height: 600px; /* 設置一個合適的高度 */}div#\:\$p>svg>foreignObject>section .free>div img:not(.emoji){width:auto;transition:transform 0.3s ease}div#\:\$p>svg>foreignObject>section .free>div img:not(.emoji){width:auto;transition:transform 0.3s ease}div#\:\$p>svg>foreignObject>section .container{display:flex}div#\:\$p>svg>foreignObject>section .half{display:flex;justify-content:center;align-items:left;gap:calc(var(--marpit-root-font-size, 1rem) * 1)}div#\:\$p>svg>foreignObject>section .half>div{flex:1;width:calc(50% - calc(var(--marpit-root-font-size, 1rem) * 0.5)); /* set width to 50% minus half the gap */padding-right:0.5em;transition:transform 0.3s ease}div#\:\$p>svg>foreignObject>section .free>div img:hover,div#\:\$p>svg>foreignObject>section .half>div:hover{transform:translateY(-10px);transform-origin:center;border-top-width:0px}div#\:\$p>svg>foreignObject>section .columns{padding-top:1em;padding-right:1em;
  /* margin-right: 1.5em; */display:flex;justify-content:center;align-items:left;gap:calc(var(--marpit-root-font-size, 1rem) * 1)}div#\:\$p>svg>foreignObject>section .columns>div img:not(.emoji){display:block;margin:0 auto;max-width:100%;height:auto}div#\:\$p>svg>foreignObject>section .columns>div{flex:1;width:calc(50% - calc(var(--marpit-root-font-size, 1rem) * 0.5)); /* set width to 50% minus half the gap */transition:transform 0.3s ease;padding-right:0.5em}
/* .columns div:not(:last-child) { */
/*   border-right: 1px dashed #2d696a; */
/* } */div#\:\$p>svg>foreignObject>section .columns div:not(:last-child){position:relative}div#\:\$p>svg>foreignObject>section .columns div:not(:last-child):after{content:"";position:absolute;right:0;top:30px; /* Start 10px from the top */bottom:30px; /* End 10px from the bottom */border-right:1px dashed #2d696a;width:0 /* Ensures the pseudo-element is a line */}div#\:\$p>svg>foreignObject>section .columns div:hover{transform:translateY(-5px);transform-origin:center;border-top-width:0px}div#\:\$p>svg>foreignObject>section hr{border:1px solid var(--JAMA-blue)}div#\:\$p>svg>foreignObject>section .dash{border:none;border-top:1px dashed #2d696a;height:0;margin:0.4em 0}div#\:\$p>svg>foreignObject>section .centered-content{display:flex;flex-direction:column;justify-content:center;height:600px /* 設置一個合適的高度 */}div#\:\$p>svg>foreignObject>section a{color:var(--JAMA-cyan)}div#\:\$p>svg>foreignObject>section ul li:hover::marker{transform:scale(1.5);color:#ffb703}div#\:\$p>svg>foreignObject>section li{transition:opacity 0.3s ease;transition:transform 0.3s ease}div#\:\$p>svg>foreignObject>section li::marker{color:#2d696a}div#\:\$p>svg>foreignObject>section li:hover{
  /* transform: translateX(-5px); */
  /* transform: scale(1.05); */transition:transform 0.3s ease;text-decoration:underline;text-decoration-color:#6c9a77;text-decoration-style:solid;text-decoration-thickness:1px}div#\:\$p>svg>foreignObject>section li[data-bespoke-marp-fragment=active]{opacity:1;transition:transform 0.3s ease}div#\:\$p>svg>foreignObject>section li[data-bespoke-marp-fragment=inactive]{transition:transform 0.3s ease;visibility:visible;opacity:0.2}div#\:\$p>svg>foreignObject>section :is(pre,marp-pre) ol li>:is(span,marp-span){transition:transform 0.5s ease}div#\:\$p>svg>foreignObject>section :is(pre,marp-pre) ol li>:is(span,marp-span):hover{font-weight:800;transition:transform 0.3s ease;transform:translateX(40px);
  /* color: var(--JAMA-green); */color:#ffb703}div#\:\$p>svg>foreignObject>section :is(pre,marp-pre) ol li:hover:before{color:#ffb703}div#\:\$p>svg>foreignObject>section :is(pre,marp-pre) ol li :is(span,marp-span)[data-marp-line-number]:hover{transform:scale(1.2)}div#\:\$p>svg>foreignObject>section td:hover{
  /* box-shadow: 12px 2px 15px rgba(0, 0, 0, 0.3); */color:#2d696a;border:2px solid #2d696a;background-color:white; /* sets the background color of the table header */transition:opacity 0.5s ease}div#\:\$p>svg>foreignObject>section tr:hover{transition:transform 0.3s ease}div#\:\$p>svg>foreignObject>section table:hover{
  /* box-shadow: 12px 2px 15px rgba(0, 0, 0, 0.3); */transform:scale(1.01);transition:transform 0.2s ease;box-shadow:0 8px 17px 2px rgba(0,0,0,0.14),0 3px 14px 2px rgba(0,0,0,0.12),0 5px 5px -3px rgba(0,0,0,0.2)}
/* blockquote:hover { */
/*   transform: translateY(-20); */
/*   transition: transform 0.3s ease; */
/*   padding: 0.4em 0.8em 0.4em 0.8em; */
/* } */div#\:\$p>svg>foreignObject>section button{display:inline-block;outline:none;cursor:pointer;font-size:inherit;line-height:1;border-radius:200px;transition-property:background-color,border-color,color,box-shadow,filter;transition-duration:0.3s;border:1px solid transparent;letter-spacing:2px;min-width:160px;text-transform:uppercase;white-space:normal;font-weight:700;text-align:center;padding:2px 2px;margin-left:20px;color:#fff;background-color:#2d696a;height:48px;div#\:\$p>svg>foreignObject>section :hover{transform:scale(1.04);background-color:#2d696a}}div#\:\$p>svg>foreignObject>section .container{border:1px solid black;margin:10px}div#\:\$p>svg>foreignObject>section summary{color:#2d696a;font-weight:bold}
/* line num in codebox  */div#\:\$p>svg>foreignObject>section :is(pre,marp-pre) ol{all:unset;display:grid;grid-template-columns:auto 1fr;counter-reset:line-number 0}div#\:\$p>svg>foreignObject>section code ol{padding-right:2.5em}div#\:\$p>svg>foreignObject>section :is(pre,marp-pre) ol li{display:contents;color:#fff;font-weight:500;
  /* font-family: "Inter", sans-serif; */font-family:"Overpass Mono",monospace}div#\:\$p>svg>foreignObject>section :is(pre,marp-pre) ol li :is(span,marp-span)[data-marp-line-number]:before{display:block;content:counter(line-number);counter-increment:line-number;text-align:right;color:#595959;font-weight:800;background-color:#222;border-right:5px solid #595959;margin-right:0.51em;padding-right:0.51em;padding-left:0.51em}div#\:\$p>svg>foreignObject>section img[alt*=emojik]{animation:move 2.5s infinite cubic-bezier(0.6,0.05,0.4,0.95)}div#\:\$p>svg>foreignObject>section img[alt*=RLQ]{position:absolute; /* sets the position of the element to absolute */right:80px;bottom:80px}div#\:\$p>svg>foreignObject>section img[alt*=RUQ]{position:absolute; /* sets the position of the element to absolute */right:80px;top:80px}@keyframes fade-in{0%{opacity:0;transform:translateY(-20px)}to{opacity:1;transform:translateY(0)}}@keyframes move{0%{transform:translateX(0)}50%{transform:translateX(-20px)}to{transform:translateX(0)}}@keyframes slideInRight{0%{transform:translateX(100%)}to{transform:translateX(0)}}@keyframes fadeIn{0%{opacity:0}to{opacity:1}}@keyframes fade{0%{opacity:0}50%{opacity:1}to{opacity:0}}div#\:\$p>svg>foreignObject>section svg.markmap{width:200%}div#\:\$p>svg>foreignObject>section img{animation-name:fadeIn;animation-duration:0.2s;animation-fill-mode:both;animation-delay:0.3s}div#\:\$p>svg>foreignObject>section div[class^=admonition]{margin-left:80px;max-width:80%;animation-name:fadeIn;animation-duration:0.3s;animation-fill-mode:both;animation-delay:0.5s;transition:transform 0.3s ease}div#\:\$p>svg>foreignObject>section div[class^=admonition]>p>strong{font-weight:bold}
/* div[class^="admonition"] > p  { */
/* } */div#\:\$p>svg>foreignObject>section div[class^=admonition]:hover{
  /* box-shadow: 12px 2px 15px rgba(0, 0, 0, 0.3); */
  /* material style shadow */transform:translateX(20px);transition:transform 0.3s ease;box-shadow:0 8px 17px 2px rgba(0,0,0,0.14),0 3px 14px 2px rgba(0,0,0,0.12),0 5px 5px -3px rgba(0,0,0,0.2)}div#\:\$p>svg>foreignObject>section p.admonition-title:before{padding-left:20px;padding-top:4px;animation:fade 2s cubic-bezier(0.4,0,0.2,1) infinite}div#\:\$p>svg>foreignObject>section .task-list-item-checkbox{transform:scale(1.5)}div#\:\$p>svg>foreignObject>section .box{width:40%;margin:0 auto;background:rgba(255,255,255,0.2);padding:35px;border:2px solid #fff;border-radius:20px/50px;background-clip:padding-box;text-align:center}div#\:\$p>svg>foreignObject>section .button{font-size:1em;padding:2px;border:2px solid #06d85f;text-decoration:none;cursor:pointer;transition:all 0.3s ease-out}div#\:\$p>svg>foreignObject>section section.button{--marpit-root-font-size:1em}div#\:\$p>svg>foreignObject>section .button:hover{background:#06d85f}div#\:\$p>svg>foreignObject>section .overlay{position:fixed;top:0;bottom:0;left:0;right:0;background:rgba(0,0,0,0.7);transition:opacity 500ms;visibility:hidden;opacity:0}div#\:\$p>svg>foreignObject>section .overlay:target{visibility:visible;opacity:1}div#\:\$p>svg>foreignObject>section .popup{margin:70px auto;padding:20px;background:#fff;border-radius:5px;width:70%;position:relative;transition:all 5s ease-in-out}div#\:\$p>svg>foreignObject>section .popup :is(h2,marp-h2){margin-top:0;color:#333}div#\:\$p>svg>foreignObject>section .popup .close{position:absolute;top:20px;right:30px;transition:all 200ms;font-size:30px;font-weight:bold;text-decoration:none;color:#333}div#\:\$p>svg>foreignObject>section .popup div#\:\$p>svg>foreignObject>section section.close{--marpit-root-font-size:30px}div#\:\$p>svg>foreignObject>section .popup .close:hover{color:#06d85f}div#\:\$p>svg>foreignObject>section .popup .content{max-height:30%;overflow:auto}@media screen and (max-width:1000px){div#\:\$p>svg>foreignObject>section .box{width:70%}div#\:\$p>svg>foreignObject>section .popup{width:70%}}div#\:\$p>svg>foreignObject>section .markmap>svg{width:100%;height:550px;font:300 16px/20px sans-serif}div#\:\$p>svg>foreignObject>section .material-symbols-outlined{font-size:40px;color:#2d696a;margin-bottom:2px;animation:pulse 1.5s infinite cubic-bezier(0.6,0.05,0.4,0.95);font-variation-settings:"FILL" 1,"wght" 500,"GRAD" 100,"opsz" 48}div#\:\$p>svg>foreignObject>section section.material-symbols-outlined{--marpit-root-font-size:40px}div#\:\$p>svg>foreignObject>section .bx{color:#2d696a}@keyframes pulse{0%{font-variation-settings:"wght" 200}50%{font-variation-settings:"wght" 500}to{font-variation-settings:"wght" 200}}

/* @theme ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g */div#\:\$p>svg>foreignObject>section[data-marpit-advanced-background=background]{columns:initial!important;display:block!important;padding:0!important}div#\:\$p>svg>foreignObject>section[data-marpit-advanced-background=background]:after,div#\:\$p>svg>foreignObject>section[data-marpit-advanced-background=background]:before,div#\:\$p>svg>foreignObject>section[data-marpit-advanced-background=content]:after,div#\:\$p>svg>foreignObject>section[data-marpit-advanced-background=content]:before{display:none!important}div#\:\$p>svg>foreignObject>section[data-marpit-advanced-background=background]>div[data-marpit-advanced-background-container]{all:initial;display:flex;flex-direction:row;height:100%;overflow:hidden;width:100%}div#\:\$p>svg>foreignObject>section[data-marpit-advanced-background=background]>div[data-marpit-advanced-background-container][data-marpit-advanced-background-direction=vertical]{flex-direction:column}div#\:\$p>svg>foreignObject>section[data-marpit-advanced-background=background][data-marpit-advanced-background-split]>div[data-marpit-advanced-background-container]{width:var(--marpit-advanced-background-split,50%)}div#\:\$p>svg>foreignObject>section[data-marpit-advanced-background=background][data-marpit-advanced-background-split=right]>div[data-marpit-advanced-background-container]{margin-left:calc(100% - var(--marpit-advanced-background-split, 50%))}div#\:\$p>svg>foreignObject>section[data-marpit-advanced-background=background]>div[data-marpit-advanced-background-container]>figure{all:initial;background-position:center;background-repeat:no-repeat;background-size:cover;flex:auto;margin:0}div#\:\$p>svg>foreignObject>section[data-marpit-advanced-background=background]>div[data-marpit-advanced-background-container]>figure>figcaption{position:absolute;border:0;clip:rect(0,0,0,0);height:1px;margin:-1px;overflow:hidden;padding:0;white-space:nowrap;width:1px}div#\:\$p>svg>foreignObject>section[data-marpit-advanced-background=content],div#\:\$p>svg>foreignObject>section[data-marpit-advanced-background=pseudo]{background:transparent!important}div#\:\$p>svg>foreignObject>section[data-marpit-advanced-background=pseudo],div#\:\$p>svg[data-marpit-svg]>foreignObject[data-marpit-advanced-background=pseudo]{pointer-events:none!important}div#\:\$p>svg>foreignObject>section[data-marpit-advanced-background-split]{width:100%;height:100%}</style></head><body><div class="bespoke-progress-parent"><div class="bespoke-progress-bar"></div></div><div class="bespoke-marp-osc"><button data-bespoke-marp-osc="prev" tabindex="-1" title="Previous slide">Previous slide</button><span data-bespoke-marp-osc="page"></span><button data-bespoke-marp-osc="next" tabindex="-1" title="Next slide">Next slide</button><button data-bespoke-marp-osc="fullscreen" tabindex="-1" title="Toggle fullscreen (f)">Toggle fullscreen</button><button data-bespoke-marp-osc="presenter" tabindex="-1" title="Open presenter view (p)">Open presenter view</button></div><div id=":$p"><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="1" data-header="KFSYSCC morning meeting" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" style="--header:KFSYSCC morning meeting;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;">
<header>KFSYSCC morning meeting</header>
<h4 class='today'>2023-12-24</h4><h1 is="marp-h1" data-auto-scaling id="treatment-of-brearly-triple-negative-brbreast-cancer" tabindex="-1">Treatment of <br /><strong>Early</strong> Triple-Negative <br />Breast Cancer</h1>
<h2 id="beginning-end-and-everything-in-between" tabindex="-1">Beginning, End, and Everything in Between</h2>
<br />
<h6 id="fellow-1-%E6%9E%97%E5%8D%94%E9%9C%86" tabindex="-1">Fellow 1 林協霆</h6>
<h6 id="%E9%8D%BE%E5%A5%87%E5%B3%B0%E9%86%AB%E5%B8%AB" tabindex="-1">鍾奇峰醫師</h6>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="2" data-paginate="true" data-header="Introduction" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="2" style="--paginate:true;--header:Introduction;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>Introduction</header>

<h1 id="introduction" tabindex="-1">INTRODUCTION</h1>
<div class="free"><div>
<ul>
<li>early stage TNBC, remains the most challenging breast cancer subtype to treat</li>
<li>limited targeted therapies</li>
<li>higher rates of relapse and</li>
<li>greater risk of mortality.</li>
</ul>
</div><div>

<p><img src="https://i.imgur.com/LElsvJ6.png" alt="Figure:" style="height:450px;" /></p>
</div></div>
</div></div>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="3" data-paginate="true" data-header="Introduction" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="3" style="--paginate:true;--header:Introduction;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>Introduction</header>
<h2 id="intrinsic-molecular-subtypes-of-breast-cancer" tabindex="-1">Intrinsic molecular subtypes of breast cancer</h2>
<div class="free"><div>
<h4 id="tnbc-is-a-heterogeneous-group" tabindex="-1">TNBC is a heterogeneous group</h4>
<p><img src="https://i.imgur.com/6CKsHWU.png" alt="Figure:" style="height:430px;" /></p>
</div><div>
<p><img src="https://i.imgur.com/tOa1tXM.png" alt="Figure:" style="height:430px;" /></p>
</div></div>
</div></div>
<blockquote>
<p>Zagami P, Carey LA. Triple negative breast cancer: Pitfalls and progress. npj Breast Cancer. 2022;8(1):1-10. doi:10.1038/s41523-022-00468-0</p>
</blockquote>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="4" data-paginate="true" data-header="Introduction" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="4" style="--paginate:true;--header:Introduction;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>Introduction</header>
<div class="columns"><div>
<h2 id="key-points-on-tnbc" tabindex="-1">Key Points on TNBC</h2>
<ul>
<li>TNBC: 10%-15% of breast cancer</li>
<li>The prevalence of TNBC is higher in:
<ul>
<li>young women (50 years and younger)</li>
<li>BRCA 1 mutation carriers</li>
<li>African American women</li>
</ul>
</li>
<li>adverse biological features
<ul>
<li>high grade,</li>
<li>high mitotic count</li>
<li>p53 positivity</li>
</ul>
</li>
</ul>
</div><div>
<p><img src="https://i.imgur.com/aqQPr9B.png" alt="Figure:" style="height:570px;" /></p>
</div></div>
</div></div>
<blockquote>
<p>CAREY, Lisa, et al. Triple-negative breast cancer: disease entity or title of convenience?. Nature reviews Clinical oncology, 2010, 7.12: 683-692.</p>
</blockquote>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="5" data-paginate="true" data-header="Introduction" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="5" style="--paginate:true;--header:Introduction;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>Introduction</header>
<h2 id="breast-cancer-staging-ajcc-8th" tabindex="-1">Breast Cancer staging: AJCC 8th</h2>
<div class="columns"><div>
<p><img src="https://i.imgur.com/mafylXU.png" alt="Figure:" style="height:350px;" /></p>
</div><div>
<p><img src="https://i.imgur.com/HqjMjQi.png" alt="Figure:" style="height:350px;" /></p>
</div></div>
</div></div>
<ul>
<li>pN1 – <strong>1-3</strong> axillary LN</li>
<li>pN2 – <strong>4-9</strong> axillary LN, or ⊕ ipsilateral internal mammary LN</li>
</ul>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="6" data-paginate="true" data-header="Introduction" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="6" style="--paginate:true;--header:Introduction;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>Introduction</header>
<h2 id="breast-carcinoma-tnm-anatomic-stage-group-ajcc-uicc-8th-edition" tabindex="-1">Breast carcinoma TNM anatomic stage group AJCC UICC 8th edition</h2>
<div class="free"><div>
<p><img src="https://i.imgur.com/C4N5c5n.png" alt="Figure:" style="height:450px;" /></p>
</div><div>
<ul>
<li>N1: Stage II+</li>
<li>T2: Stage II+</li>
<li>T3N0: Stage II <img class="emoji" draggable="false" alt="✨" src="https://cdn.jsdelivr.net/gh/jdecked/twemoji@14.1.2/assets/svg/2728.svg" data-marp-twemoji=""/></li>
<li>N2: Stage III+</li>
<li>T4: Stage III+</li>
</ul>
<p><img src="https://i.imgur.com/o3mstgT.png" alt="Figure:" style="height:200px;" /></p>
</div></div>
</div></div>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="7" data-paginate="true" data-header="Introduction" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="7" style="--paginate:true;--header:Introduction;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>Introduction</header>
<h2 id="risk-profile-and-associated-survival-outcomes" tabindex="-1">Risk profile and associated survival outcomes</h2>
<div class="free"><div>
<p><img src="https://i.imgur.com/xu6ncCt.png" alt="Figure:" style="width:720px;" /><br />
<img src="https://i.imgur.com/Zw9Sr0o.png" alt="Figure:" style="width:722px;" /></p>
</div><div>
<h2 id="1-points" tabindex="-1">1 points</h2>
<ul>
<li>Grade 3</li>
<li>ER negative ⊖</li>
<li>HER2 negative ⊖</li>
<li>e.g. IIIC 3 points: 5yDSS:</li>
</ul>
<p><img src="https://i.imgur.com/3ri0lv7.png" alt="Figure:" style="height:250px;" /></p>
</div></div>
</div></div>
<blockquote>
<p>MD Anderson validation of biomarkers in TNM 8th edition staging</p>
</blockquote>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section data-paginate="true" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="8" style="--paginate:true;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;--marpit-advanced-background-split:60%;" data-marpit-pagination-total="70" data-marpit-advanced-background="background" data-marpit-advanced-background-split="right"><div data-marpit-advanced-background-container="true" data-marpit-advanced-background-direction="horizontal"><figure style="background-image:url(&quot;https://i.imgur.com/aHVNCZP.png&quot;);background-size:auto 650px;"></figure></div></section></foreignObject><foreignObject width="40%" height="720"><section id="8" data-paginate="true" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="8" style="--paginate:true;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;--marpit-advanced-background-split:60%;" data-marpit-pagination-total="70" data-marpit-advanced-background="content" data-marpit-advanced-background-split="right">
<h2 id="the-role-of-br-neoadjuvant-therapy-br-nac-in-early-breast-cancer" tabindex="-1">The role of <br /> neoadjuvant therapy <br /> (NAC) in early breast cancer</h2>

<blockquote>
<p>DEROUANE, Françoise, et al. Predictive biomarkers of response to neoadjuvant chemotherapy in breast cancer: current and future perspectives for precision medicine. Cancers, 2022, 14.16: 3876.</p>
</blockquote>
</section>
</foreignObject><foreignObject width="1280" height="720" data-marpit-advanced-background="pseudo"><section data-paginate="true" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="8" style="" data-marpit-pagination-total="70" data-marpit-advanced-background="pseudo" data-marpit-advanced-background-split="right"></section></foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="9" data-paginate="true" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="9" style="--paginate:true;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<h2 id="kfsyscc-guide-2023-for-now" tabindex="-1">KFSYSCC guide 2023 (for now)</h2>
<h4 id="early-tnbc" tabindex="-1">early TNBC</h4>
<p><img src="./src/Early_TNBC_III.svg" alt="title: Early_TNBC_III" style="height:200px;" /></p>
<hr />
<div class="columns"><div>
<ul>
<li>Stage IIA: T1N1M0, T2N0M0</li>
<li>Stage IIB: T2N1M0</li>
<li>Stage III T3N0M0</li>
</ul>
</div><div>
<p>AC: doxorubicin and cyclophosphamide<br />
TAXOTERE: docetaxel<br />
CPPD: cisplatin<br />
pCR: pathological complete response</p>
</div></div>
</div></div>
<blockquote>
<p><a href="./src/Early_TNBC_III.gv">Early TNBC Stage III Ⓒ Hsieh-Ting Lin</a></p>
</blockquote>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="10" data-paginate="true" data-header="pCR" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="10" style="--paginate:true;--header:pCR;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>pCR</header>

<h1 is="marp-h1" data-auto-scaling id="complete-brpathologic-response" tabindex="-1">Complete <br />Pathologic Response</h1>
<h2 id="why-complete-pathologic-response-matter" tabindex="-1">Why complete pathologic response matter?</h2>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="11" data-paginate="true" data-header="pCR" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="11" style="--paginate:true;--header:pCR;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>pCR</header>
<h2 id="complete-pathologic-response-pcr-the-goal-of-nac" tabindex="-1"><strong>Complete Pathologic Response</strong> (pCR): the goal of NAC</h2>
<h4 id="" tabindex="-1"></h4>
<ul>
<li><strong>no invasive residual disease</strong> in the <strong>breast</strong> or the <strong>lymph nodes</strong> after completing neoadjuvant therapy
<ul>
<li>ypT0 ypN0</li>
<li>ypT0/is ypN0</li>
</ul>
</li>
<li>The achievement of a pathologic complete response (pCR) after NAC
<ul>
<li>marker for systemic therapy sensitivity.</li>
</ul>
</li>
<li>pCR a/w improved long-term outcomes in TNBCs, <strong>both EFS and OS</strong>
<ul>
<li>HR:
<ul>
<li>EFS: 0.48, a.k.a. 降低 5 成 2 的復發機會</li>
<li>OS: 0.36, a.k.a. 降低 6 成 4 的死亡率</li>
</ul>
</li>
</ul>
</li>
</ul>
<blockquote>
<p>CORTAZAR, Patricia, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. The Lancet, 2014, 384.9938: 164-172.</p>
</blockquote>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="12" data-paginate="true" data-header="pCR" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="12" style="--paginate:true;--header:pCR;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>pCR</header>
<p><img src="https://i.imgur.com/GQtvCKx.png" alt="Figure:" style="height:550px;" /></p>
<blockquote>
<p>CORTAZAR, Patricia, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. The Lancet, 2014, 384.9938: 164-172.</p>
</blockquote>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="13" data-paginate="true" data-header="pCR" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="13" style="--paginate:true;--header:pCR;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>pCR</header>
<p><img src="https://i.imgur.com/5kNnfAl.png" alt="Figure:" style="height:550px;" /></p>
<h4 id="overall-survival-in-subgroup-between-patient-with-or-without-pcr" tabindex="-1">Overall survival in subgroup between patient with or without pCR</h4>
<br />
<blockquote>
<p>Figure 4: Percentage of patients achieving pathological complete response (A) and HRs for overall survival</p>
</blockquote>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="14" data-paginate="true" data-header="pCR" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="14" style="--paginate:true;--header:pCR;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>pCR</header>
<h2 id="the-degree-of-response-has-been-evaluated-by" tabindex="-1">The degree of response has been evaluated by</h2>
<h1 id="residual-cancer-burden-rcb" tabindex="-1"><strong>residual cancer burden</strong> (RCB)</h1>
<div class="free"><div>
<ul>
<li>
<p>(2) Primary Tumor Bed</p>
<ul>
<li>Primary Tumor Bed Area:</li>
<li>Overall Cancer Cellularity(as percentage of area)</li>
<li>Percentage of Cancer That Is in situ Disease</li>
</ul>
</li>
</ul>
</div><div>
<ul>
<li>(2) Lymph Nodes
<ul>
<li>Number of Positive Lymph Nodes</li>
<li>Diameter of Largest Metastasis</li>
<li>Residual Cancer Burden</li>
<li>Residual Cancer Burden Class</li>
</ul>
</li>
</ul>
</div></div>
</div></div>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="15" data-paginate="true" data-header="pCR" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="15" style="--paginate:true;--header:pCR;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>pCR</header>
<h5 id="prognostic-value-of-rcb-score-and-rcb-class-in-the-overall-pooled-analysis-cohort-efs-distance-relpase-free-survival" tabindex="-1">Prognostic value of RCB score and RCB class in the overall pooled analysis cohort: EFS, Distance Relpase-free survival</h5>
<div class="free"><div>
<p><img src="https://i.imgur.com/d929XXp.png" alt="" style="height:500px;" /></p>
</div><div>
<p><img src="https://i.imgur.com/3m7laww.png" alt="Figure:" style="height:500px;" /></p>
</div></div>
</div></div>
<blockquote>
<p>YAU, Christina, et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. The Lancet Oncology, 2022, 23.1: 149-160.</p>
</blockquote>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="16" data-paginate="true" data-header="NAC" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="16" style="--paginate:true;--header:NAC;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>NAC</header>

<h1 id="neoadjuvant-chemotherapy-in-tnbc" tabindex="-1">Neoadjuvant chemotherapy in TNBC</h1>
<p><img src="https://i.imgur.com/7O27dPh.png" alt="Figure:" style="height:350px;" /></p>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="17" data-paginate="true" data-header="CALGB 9344" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="17" style="--paginate:true;--header:CALGB 9344;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>CALGB 9344</header>

<h2 id="calgb-9344intergroup-0148" tabindex="-1">CALGB 9344/Intergroup 0148</h2>
<div class="free"><div>
<p><img src="./src/CALGB9344.svg" alt="title: CALGB9344" style="height:480px;" /></p>
</div><div>
<h3 id="randomized-trial" tabindex="-1">randomized trial</h3>
<ul>
<li>A = Doxorubicin (doses mg/m2)</li>
<li>C = Cyclophosphamide (600 mg/m2)</li>
<li>P = Paclitaxel (175 mg/m2, 3 hour infusion)</li>
</ul>
</div></div>
</div></div>
<blockquote>
<p><a href="./src/CALGB9344.gv">Credit: Hsieh-Ting Lin, CALGB9344, CC-BY-NC-ND-2.0, via Graphviz</a></p>
</blockquote>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="18" data-paginate="true" data-header="CALGB 9344" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="18" style="--paginate:true;--header:CALGB 9344;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>CALGB 9344</header>
<h3 id="result" tabindex="-1">Result</h3>
<div class="free"><div>
<p><img src="https://i.imgur.com/Ycvd7ag.png" alt="right" style="height:550px;" /></p>
</div><div>
<ul>
<li>± Paclitaxel in Node-Positive Breast Cancer</li>
<li>adjuvant paclitaxel: <img class="emoji" draggable="false" alt="👍" src="https://cdn.jsdelivr.net/gh/jdecked/twemoji@14.1.2/assets/svg/1f44d.svg" data-marp-twemoji=""/> survival benefit LN positive BC</li>
<li><img class="emoji" draggable="false" alt="⚠️" src="https://cdn.jsdelivr.net/gh/jdecked/twemoji@14.1.2/assets/svg/26a0.svg" data-marp-twemoji=""/> except ER postive, HER2 negative group <img class="emoji" draggable="false" alt="👉" src="https://cdn.jsdelivr.net/gh/jdecked/twemoji@14.1.2/assets/svg/1f449.svg" data-marp-twemoji=""/> Fig. B</li>
</ul>
</div></div>
</div></div>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="19" data-paginate="true" data-header="GeparSixto" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="19" style="--paginate:true;--header:GeparSixto;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>GeparSixto</header>

<h2 id="the-function-of-platinum-based-therapies-in-neoadjuvant" tabindex="-1">The Function of Platinum-Based Therapies in neoadjuvant</h2>

<h3 id="geparsixto-randomized-phase-ii-study" tabindex="-1">GeparSixto, randomized phase II study</h3>
<ul>
<li>neoadjuvant <strong>carboplatin</strong> in stage II or III <strong>TNBC and HER2-positive</strong></li>
<li>18 weeks of paclitaxel 80 mg/m2 IV once weekly and non-pegylated liposomal doxorubicin 20 mg/m2 IV once weekly.</li>
</ul>
<hr />
<ul>
<li>Patients with TNBC received simultaneous bevacizumab 15 mg/kg IV once every 3 weeks.</li>
<li>Patients were randomly assigned to carboplatin AUC 1.5-2 mg/mL per min IV weekly (n = 296) versus no carboplatin (n = 299).</li>
<li>The pCR rate was <strong>53.2% with carboplatin</strong> versus <strong>36.9% without carboplatin</strong> (P = .005) in patients with TNBC</li>
</ul>
<div class="admonition info">
<p class="admonition-title">carboplatin in TNBC</p>
</div>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="20" data-paginate="true" data-header="GeparSixto" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="20" style="--paginate:true;--header:GeparSixto;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>GeparSixto</header>
<div class="free"><div>
<p><img src="https://i.imgur.com/8DOrP00.png" alt="Figure:" style="height:550px;" /></p>
</div><div>
<h4 id="panel-c-tnbc" tabindex="-1">Panel C: TNBC</h4>
<p><img src="https://i.imgur.com/1yPcIsj.png" alt="Figure:" style="height:500px;" /></p>
</div></div>
</div></div>
<blockquote>
<p>mRTDI=mean relative total dose intensity. TNBC=triple-negative breast cancer. pCR=pathological complete response<br />
<strong>y-axis: pCR rate</strong></p>
</blockquote>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section data-paginate="true" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="21" style="--paginate:true;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;--marpit-advanced-background-split:50%;" data-marpit-pagination-total="70" data-marpit-advanced-background="background" data-marpit-advanced-background-split="right"><div data-marpit-advanced-background-container="true" data-marpit-advanced-background-direction="horizontal"><figure style="background-image:url(&quot;https://i.imgur.com/AYiaSOE.png&quot;);background-size:auto 600px;"></figure></div></section></foreignObject><foreignObject width="50%" height="720"><section id="21" data-paginate="true" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="21" style="--paginate:true;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;--marpit-advanced-background-split:50%;" data-marpit-pagination-total="70" data-marpit-advanced-background="content" data-marpit-advanced-background-split="right">
<h3 id="similarly-the-brightness-trial-a-phase-iii-randomized-study" tabindex="-1">Similarly, the BrighTNess trial, a phase III randomized study</h3>
<ul>
<li>Phase 3, randomized, double-blind, placebo-controlled trial</li>
<li>Patients aged 18 years and older</li>
<li>Previously untreated histologically or cytologically confirmed clinical stage II–III triple-negative breast cancer</li>
</ul>
<hr />
<ul>
<li>
<p>Paclitaxel + carboplatin + veliparib</p>
</li>
<li>
<p>Paclitaxel + carboplatin</p>
</li>
<li>
<p>Paclitaxel</p>
</li>
<li>
<p>4.5y, HR for EFS was 0.63</p>
</li>
</ul>
</section>
</foreignObject><foreignObject width="1280" height="720" data-marpit-advanced-background="pseudo"><section data-paginate="true" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="21" style="" data-marpit-pagination-total="70" data-marpit-advanced-background="pseudo" data-marpit-advanced-background-split="right"></section></foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="22" data-paginate="true" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="22" style="--paginate:true;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<div class="free"><div>
<p><img src="https://i.imgur.com/NBehsk2.png" alt="" style="height:600px;" /></p>
</div><div>
<p><img src="https://i.imgur.com/i99tuDA.jpg" alt="Figure:" style="height:330px;" /></p>
<ul>
<li><code>A</code>: 3 v 2 <code>B</code>: 3 v 1 <code>C</code>: 2 v 1</li>
<li>carboplatin improve the pCR but veliparib not</li>
</ul>
</div></div>
</div></div>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="23" data-paginate="true" data-header="Wrap up" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="23" style="--paginate:true;--header:Wrap up;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>Wrap up</header>

<h2 id="short-wrap-up" tabindex="-1">Short Wrap up</h2>
<div class="columns"><div>
<ul>
<li>Patients experiencing pathologic complete response had superior 5-year overall survival (OS)</li>
<li>Carboplatin:
<ul>
<li>For patients who may not be eligible for ICI, a platinum-based regimens in the NAC setting have demonstrated robust responses <strong>53% <img class="emoji" draggable="false" alt="🆚" src="https://cdn.jsdelivr.net/gh/jdecked/twemoji@14.1.2/assets/svg/1f19a.svg" data-marp-twemoji=""/> 31%</strong></li>
</ul>
</li>
</ul>
</div><div>

<p><img src="https://i.imgur.com/8nH5Fjk.jpg" alt="Figure:" style="height:500px;" /></p>
</div></div>
</div></div>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="24" data-paginate="true" data-header="ICI" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="24" style="--paginate:true;--header:ICI;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>ICI</header>

<h1 id="chemoimmunotherapy-in-stage-ii-and-iii-tnbc" tabindex="-1">Chemoimmunotherapy in Stage II and III TNBC</h1>
<h2 id="a-paradigm-shift" tabindex="-1">A Paradigm Shift</h2>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section data-paginate="true" data-header="ICI" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="25" style="--paginate:true;--header:ICI;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70" data-marpit-advanced-background="background"><div data-marpit-advanced-background-container="true" data-marpit-advanced-background-direction="horizontal"><figure style="background-image:url(&quot;https://i.imgur.com/Lg41ca4.png&quot;);background-size:contain;"></figure></div></section></foreignObject><foreignObject width="1280" height="720"><section id="25" data-paginate="true" data-header="ICI" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="25" style="--paginate:true;--header:ICI;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70" data-marpit-advanced-background="content">
<header>ICI</header>
</section>
</foreignObject><foreignObject width="1280" height="720" data-marpit-advanced-background="pseudo"><section data-paginate="true" data-header="ICI" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="25" style="" data-marpit-pagination-total="70" data-marpit-advanced-background="pseudo"></section></foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="26" data-paginate="true" data-header="ICI" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="26" style="--paginate:true;--header:ICI;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>ICI</header>
<p><img src="https://i.imgur.com/64B2sQ1.png" alt="" style="height:350px;" /></p>
<p><code>內專 107</code>以下治療&quot;藥劑&quot;與免疫或分子&quot;標 靶&quot;的配對，下列那些為真？<br />
(1). Afatinib 與 EGFR<br />
(2). Ipilimumab 與 PD-L1<br />
(3). Trastuzumab 與 HER-2<br />
(4). Rituximab 與 CD20<br />
(5). Pembrolizumab 與 PD-1</p>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="27" data-paginate="true" data-header="ICI" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="27" style="--paginate:true;--header:ICI;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>ICI</header>
<h2 id="phase-ii-i-spy-2-trial-improved-outcomes-with-combination-pembrolizumab--nac-in-etnbc" tabindex="-1">Phase II, I-SPY 2 trial improved outcomes with combination Pembrolizumab + NAC in ETNBC</h2>
<br />
<div class="free"><div>
<h3 id="estimated-pcr-rate" tabindex="-1">Estimated pCR Rate</h3>
<h4 id="95-probabily-interval" tabindex="-1">(95% Probabily Interval)</h4>
<table>
<thead>
<tr>
<th>Signature</th>
<th>Pembrolizumab + <br />Standard Therapy</th>
<th>Standard Therapy<br />Alone</th>
</tr>
</thead>
<tbody>
<tr>
<td>TNBC</td>
<td><strong>0.60</strong> (0.43 – 0.78)</td>
<td><strong>0.20</strong> (0.06 – 0.33)</td>
</tr>
<tr>
<td>All HER2-</td>
<td>0.46 (0.34 – 0.58)</td>
<td>0.16 (0.06 – 0.27)</td>
</tr>
<tr>
<td>HR+/HER2-</td>
<td>0.34 (0.19 – 0.48)</td>
<td>0.13 (0.03 – 0.24)</td>
</tr>
</tbody>
</table>
</div><div>
<p><img src="https://i.imgur.com/b2nNhCl.png" alt="Figure:" style="height:250px;" /></p>
</div></div>
</div></div>
<ul>
<li>990 patients</li>
</ul>
<blockquote>
<p>Wang, H., &amp; Yee, D. (2019). I-SPY 2: a neoadjuvant adaptive clinical trial designed to improve outcomes in high-risk breast cancer. Current breast cancer reports, 11, 303-310.</p>
</blockquote>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="28" data-paginate="true" data-header="GeparNUEVO" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="28" style="--paginate:true;--header:GeparNUEVO;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>GeparNUEVO</header>

<h2 id="neoadjuvant-durvalumab-improves-survival-in-early-triple-negative-breast-cancer-independent-of-pathological-complete-response" tabindex="-1">Neoadjuvant <strong>Durvalumab</strong> improves survival in early triple-negative breast cancer independent of pathological complete response</h2>
<h4 id="phase-ii-geparnuevo-study" tabindex="-1">phase II GeparNuevo study</h4>
<p><img src="https://i.imgur.com/cn01MVn.png" alt="Figure:" style="width:1150px;" /></p>
<blockquote>
<p>Loibl, S., et al. &quot;Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response.&quot; Annals of Oncology 33.11 (2022): 1149-1158.</p>
</blockquote>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="29" data-paginate="true" data-header="GeparNUEVO" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="29" style="--paginate:true;--header:GeparNUEVO;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>GeparNUEVO</header>
<h3 id="geparnuevo-survival-analysis-os" tabindex="-1">GeparNUEVO Survival Analysis: OS</h3>
<p><img src="https://i.imgur.com/3GmLoxD.png" alt="Figure:" style="width:1150px;" /></p>
<h3 id="pcr-rate-with-durvalumab" tabindex="-1">pCR rate with durvalumab</h3>
<ul>
<li><strong>53.4%</strong> (95% CI 42.5% to 61.4%)</li>
<li>versus placebo 44.2% (95% CI 33.5% to 55.3%)</li>
</ul>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="30" data-paginate="true" data-header="KEYNOTE-173" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="30" style="--paginate:true;--header:KEYNOTE-173;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>KEYNOTE-173</header>

<h2 id="phase-1b-open-label-multicohort-keynote-173" tabindex="-1">Phase 1b open-label, multicohort KEYNOTE-173</h2>
<p><img src="https://i.imgur.com/to329lW.png" alt="Figure:" style="height:500px;" /></p>
<blockquote>
<p>SCHMID, P., et al. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study. Annals of Oncology, 2020, 31.5: 569-581.</p>
</blockquote>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="31" data-paginate="true" data-header="KEYNOTE-173" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="31" style="--paginate:true;--header:KEYNOTE-173;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>KEYNOTE-173</header>
<h2 id="result-1" tabindex="-1">Result</h2>
<p><img src="https://i.imgur.com/SiaZcPE.jpg" alt="Figure:" style="height:450px;" /></p>
<ul>
<li><code>D</code> nab-paclitaxel 125 mg/m2 qw; <code>E</code> paclitaxel 80 mg/m2 qw + carboplatin AUC5 q3w.</li>
</ul>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="32" data-paginate="true" data-header="KEYNOTE-522" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="32" style="--paginate:true;--header:KEYNOTE-522;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>KEYNOTE-522</header>

<h2 id="keynote-522-phase-iii-randomized-%F0%9F%8E%B2" tabindex="-1"><strong>KEYNOTE-522</strong>, Phase III randomized <img class="emoji" draggable="false" alt="🎲" src="https://cdn.jsdelivr.net/gh/jdecked/twemoji@14.1.2/assets/svg/1f3b2.svg" data-marp-twemoji=""/></h2>
<p><img src="https://i.imgur.com/f8dfDVA.png" alt="Figure:" style="width:1150px;" /></p>
<ul>
<li>Primary endpoints: pCR (ypT0/Tis ypN0) by local review, EFS by local review</li>
<li>Secondary endpoints: pCR (ypT0 ypN0 and ypT0/Tis), OS, EFS (PD-L1+), safety, QoL</li>
<li>Exploratory endpoints: RCB, pCR by subgroups, EFS by pCR</li>
</ul>
<blockquote>
<p>SCHMID, Peter, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. New England Journal of Medicine, 2022, 386.6: 556-567.</p>
</blockquote>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section data-paginate="true" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="33" style="--paginate:true;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;--marpit-advanced-background-split:60%;" data-marpit-pagination-total="70" data-marpit-advanced-background="background" data-marpit-advanced-background-split="right"><div data-marpit-advanced-background-container="true" data-marpit-advanced-background-direction="horizontal"><figure style="background-image:url(&quot;https://i.imgur.com/NOCTdD3.png&quot;);background-size:contain;"></figure></div></section></foreignObject><foreignObject width="40%" height="720"><section id="33" data-paginate="true" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="33" style="--paginate:true;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;--marpit-advanced-background-split:60%;" data-marpit-pagination-total="70" data-marpit-advanced-background="content" data-marpit-advanced-background-split="right">
<h2 id="characteristics-of-the-patients-at-baseline" tabindex="-1">Characteristics of the Patients at Baseline</h2>
<ul>
<li>784 patients:
<ul>
<li>the pembrolizumab–chemotherapy group</li>
</ul>
</li>
<li>390 patients:
<ul>
<li>the placebo–chemotherapy group</li>
</ul>
</li>
<li>plus paclitaxel and carboplatin</li>
<li>Stage II:
<ul>
<li>590 (75.3) and 291 (74.6)</li>
</ul>
</li>
</ul>
</section>
</foreignObject><foreignObject width="1280" height="720" data-marpit-advanced-background="pseudo"><section data-paginate="true" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="33" style="" data-marpit-pagination-total="70" data-marpit-advanced-background="pseudo" data-marpit-advanced-background-split="right"></section></foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section data-paginate="true" data-header="KEYNOTE-522" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="34" style="--paginate:true;--header:KEYNOTE-522;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70" data-marpit-advanced-background="background"><div data-marpit-advanced-background-container="true" data-marpit-advanced-background-direction="horizontal"><figure style="background-image:url(&quot;https://i.imgur.com/1VCPfv4.png&quot;);background-size:contain;"></figure></div></section></foreignObject><foreignObject width="1280" height="720"><section id="34" data-paginate="true" data-header="KEYNOTE-522" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="34" style="--paginate:true;--header:KEYNOTE-522;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70" data-marpit-advanced-background="content">
<header>KEYNOTE-522</header>
</section>
</foreignObject><foreignObject width="1280" height="720" data-marpit-advanced-background="pseudo"><section data-paginate="true" data-header="KEYNOTE-522" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="34" style="" data-marpit-pagination-total="70" data-marpit-advanced-background="pseudo"></section></foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="35" data-paginate="true" data-header="KEYNOTE-522" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="35" style="--paginate:true;--header:KEYNOTE-522;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>KEYNOTE-522</header>
<div class="free"><div>
<p><img src="https://i.imgur.com/vN9Kujo.jpg" alt="Figure:" style="height:620px;" /></p>
</div><div>
<ul>
<li>N0,</li>
<li>T3/T4</li>
<li>Q3W Carbo</li>
<li>PD-L1 ㊀</li>
<li>65+</li>
<li>ECOG: 0</li>
</ul>
</div></div>
</div></div>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section data-paginate="true" data-header="KEYNOTE-522" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="36" style="--paginate:true;--header:KEYNOTE-522;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70" data-marpit-advanced-background="background"><div data-marpit-advanced-background-container="true" data-marpit-advanced-background-direction="horizontal"><figure style="background-image:url(&quot;https://i.imgur.com/X5m4x11.png&quot;);background-size:contain;"></figure></div></section></foreignObject><foreignObject width="1280" height="720"><section id="36" data-paginate="true" data-header="KEYNOTE-522" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="36" style="--paginate:true;--header:KEYNOTE-522;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70" data-marpit-advanced-background="content">
<header>KEYNOTE-522</header>
</section>
</foreignObject><foreignObject width="1280" height="720" data-marpit-advanced-background="pseudo"><section data-paginate="true" data-header="KEYNOTE-522" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="36" style="" data-marpit-pagination-total="70" data-marpit-advanced-background="pseudo"></section></foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="37" data-paginate="true" data-header="KEYNOTE-522" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="37" style="--paginate:true;--header:KEYNOTE-522;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>KEYNOTE-522</header>
<div class="free"><div>
<p><img src="https://i.imgur.com/n3D3Twr.png" alt="" style="height:620px;" /></p>
</div><div>
<h2 id="157-%F0%9F%86%9A-238" tabindex="-1">15.7% <img class="emoji" draggable="false" alt="🆚" src="https://cdn.jsdelivr.net/gh/jdecked/twemoji@14.1.2/assets/svg/1f19a.svg" data-marp-twemoji=""/> 23.8%</h2>
<h1 id="hr-066" tabindex="-1">HR: 0.66</h1>
</div></div>
</div></div>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="38" data-paginate="true" data-header="KEYNOTE-522" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="38" style="--paginate:true;--header:KEYNOTE-522;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>KEYNOTE-522</header>

<p><img src="https://i.imgur.com/FxriMnV.png" alt="Figure:" style="height:650px;" /></p>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section data-paginate="true" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="39" style="--paginate:true;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;--marpit-advanced-background-split:70%;" data-marpit-pagination-total="70" data-marpit-advanced-background="background" data-marpit-advanced-background-split="right"><div data-marpit-advanced-background-container="true" data-marpit-advanced-background-direction="horizontal"><figure style="background-image:url(&quot;https://i.imgur.com/WfdnGHi.png&quot;);background-size:contain;"></figure></div></section></foreignObject><foreignObject width="30%" height="720"><section id="39" data-paginate="true" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="39" style="--paginate:true;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;--marpit-advanced-background-split:70%;" data-marpit-pagination-total="70" data-marpit-advanced-background="content" data-marpit-advanced-background-split="right">
<h2 id="adverse-events-in-ici" tabindex="-1">Adverse Events in ICI</h2>
<ul>
<li>Hypothyroidism
<ul>
<li>(15%)</li>
</ul>
</li>
<li>Severe skin reaction
<ul>
<li>(5.7%)</li>
</ul>
</li>
<li>Hyperthyroidism
<ul>
<li>(5.2%)</li>
</ul>
</li>
<li>Adrenal insufficiency</li>
<li>Pneumonitis</li>
<li>Thyroiditis</li>
<li>Hypophysitis</li>
</ul>
</section>
</foreignObject><foreignObject width="1280" height="720" data-marpit-advanced-background="pseudo"><section data-paginate="true" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="39" style="" data-marpit-pagination-total="70" data-marpit-advanced-background="pseudo" data-marpit-advanced-background-split="right"></section></foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="40" data-paginate="true" data-header="KEYNOTE-522" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="40" style="--paginate:true;--header:KEYNOTE-522;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>KEYNOTE-522</header>
<h2 id="hightlight-of-the-keynote-522" tabindex="-1">Hightlight of the KEYNOTE-522</h2>
<ul>
<li><strong>pt w/ pCR</strong> in both arms had improved 3-year EFS rates at
<ul>
<li><strong>94.4%</strong> with pembrolizumab and</li>
<li><strong>92.5%</strong> with placebo</li>
</ul>
</li>
<li>Conversely, the 3-year EFS rates for non-pCR patients were dismal in both arms, which were
<ul>
<li><strong>67.4%</strong> with pembrolizumab</li>
<li><strong>56.8%</strong> with placebo</li>
</ul>
</li>
<li>the addition of pembrolizumab to chemotherapy shifted more tumors to lower RCB scores of 0 or 1, conferring a better prognosis.</li>
<li>Tumors with RCB scores of 2 or III had worse outcomes in both groups, which may be an even more specific prognostic indicator than pCR versus non-pCR</li>
</ul>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="41" data-paginate="true" data-header="KEYNOTE-522" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="41" style="--paginate:true;--header:KEYNOTE-522;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>KEYNOTE-522</header>
<h2 id="phase-iii-impassion031-study" tabindex="-1">Phase III IMpassion031 study</h2>
<div class="free"><div>
<ul>
<li>333 pt<img class="emoji" draggable="false" alt="😷" src="https://cdn.jsdelivr.net/gh/jdecked/twemoji@14.1.2/assets/svg/1f637.svg" data-marp-twemoji=""/> untreated stage II–III TNBC
<ul>
<li>165 <strong>atezolizumab</strong>
<ul>
<li>840 mg IV Q2W</li>
</ul>
</li>
<li>168 placebo</li>
</ul>
</li>
<li>with <strong>nab-paclitaxel</strong> 125 mg/m2 QW x 12wks</li>
<li>follow by <strong>ddAC</strong> for 8 wks</li>
<li>increased pCR rates to
<ul>
<li><strong>58%</strong> in the CIT arm versus <strong>41%</strong></li>
</ul>
</li>
</ul>
</div><div>
<p><img src="https://i.imgur.com/sK6NpLM.png" alt="Figure:" style="height:450px;" /></p>
</div></div>
</div></div>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="42" data-paginate="true" data-header="KEYNOTE-522" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="42" style="--paginate:true;--header:KEYNOTE-522;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>KEYNOTE-522</header>
<h2 id="efs-itt-population-and-subgroups" tabindex="-1">EFS (ITT POPULATION AND SUBGROUPS)</h2>
<p>Atezolizumab provides significant pC benefit and <strong>numerically</strong> improved EFS</p>
<p><img src="https://i.imgur.com/jn5KFIf.png" alt="Figure:" style="width:1150px;" /></p>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="43" data-paginate="true" data-header="KEYNOTE-522" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="43" style="--paginate:true;--header:KEYNOTE-522;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>KEYNOTE-522</header>
<h2 id="pcr-rates-in-randomized-tnbc-neoadjuvant-studies" tabindex="-1">pCR Rates in Randomized TNBC Neoadjuvant Studies</h2>
<p><img src="https://i.imgur.com/wzDnHje.png" alt="Figure:" style="width:1150px;" /></p>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="44" data-paginate="true" data-header="Adjuvant" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="44" style="--paginate:true;--header:Adjuvant;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>Adjuvant</header>

<h1 id="adjuvant-treatment-in-etnbc" tabindex="-1">Adjuvant Treatment in ETNBC</h1>
<h2 id="pcr-vs-non-pcr" tabindex="-1">pCR v.s. non-pCR</h2>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="45" data-paginate="true" data-header="CREATE-X" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="45" style="--paginate:true;--header:CREATE-X;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>CREATE-X</header>

<h3 id="if-non-pcr" tabindex="-1">If non-PCR</h3>
<h2 id="create-x-adjuvant-capecitabine-for-breast-cancer-after-preoperative-chemotherapy" tabindex="-1">CREATE-X: Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy</h2>
<div class="free"><div>
<p><img src="./src/CREATE-X.svg" alt="title: CREATE-X" style="height:450px;" /></p>
</div><div>
<p><img src="https://i.imgur.com/HqLTWcM.png" alt="Figure:" style="height:250px;" /></p>
</div></div>
</div></div>
<blockquote>
<p><a href="./src/CREATE-X.gv">CREATE-X Ⓒ Hsieh-Ting Lin</a></p>
</blockquote>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="46" data-paginate="true" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="46" style="--paginate:true;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<h3 id="other-chemotherapy-eg-platinum-based-chemotherapy" tabindex="-1">other chemotherapy, e.g. Platinum-Based Chemotherapy?</h3>
<h2 id="ecog-acrin-ea1131-randomized-phase-iii-postoperative-trial-of-platinum-based-chemotherapy-versus-capecitabine" tabindex="-1">ECOG-ACRIN EA1131: Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine</h2>
<p>Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy</p>
<p><img src="https://i.imgur.com/IAvhNAV.png" alt="Figure:" style="width:950px;" /></p>
<blockquote>
<p>MAYER, Ingrid A., et al. Randomized phase III postoperative trial of platinum-based chemotherapy versus capecitabine in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: ECOG-ACRIN EA1131. Journal of clinical oncology, 2021, 39.23: 2539.</p>
</blockquote>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="47" data-paginate="true" data-header="CREATE-X" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="47" style="--paginate:true;--header:CREATE-X;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>CREATE-X</header>
<h3 id="ecog-acrin-ea1131-result" tabindex="-1">ECOG-ACRIN EA1131: Result</h3>
<div class="free"><div>
<p><img src="https://i.imgur.com/lArhZgb.png" alt="Figure:" style="height:500px;" /></p>
</div><div>
<h4 id="3-year-invasive-dfs" tabindex="-1">3-year invasive DFS</h4>
<ul>
<li>42% with platinum vs.</li>
<li>49% with capecitabine.</li>
</ul>
</div></div>
</div></div>
<blockquote>
<p>MAYER, Ingrid A., et al. Randomized phase III postoperative trial of platinum-based chemotherapy versus capecitabine in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: ECOG-ACRIN EA1131. Journal of clinical oncology, 2021, 39.23: 2539.</p>
</blockquote>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="48" data-paginate="true" data-header="OlympiA" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="48" style="--paginate:true;--header:OlympiA;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>OlympiA</header>

<h3 id="if-non-pcr-1" tabindex="-1">If non-PCR</h3>
<h2 id="germline-brca-mutations" tabindex="-1">Germline BRCA mutations</h2>
<h3 id="olympia-adjuvant-olaparib-with-brca1-or-brca2-mutated" tabindex="-1">Olympia: Adjuvant Olaparib with BRCA1 or BRCA2 mutated</h3>
<p><img src="https://i.imgur.com/Pxqty4a.png" alt="Figure:" style="width:1150px;" /></p>
<blockquote>
<p>TUTT, Andrew NJ, et al. Adjuvant olaparib for patients with BRCA1-or BRCA2-mutated breast cancer. New England Journal of Medicine, 2021, 384.25: 2394-2405.</p>
</blockquote>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="49" data-paginate="true" data-header="OlympiA" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="49" style="--paginate:true;--header:OlympiA;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>OlympiA</header>
<h3 id="olympia-result" tabindex="-1">OlympiA: Result</h3>
<h2 id="adjuvant-olaparib-versus-placebo" tabindex="-1">Adjuvant olaparib versus placebo</h2>
<div class="free"><div>
<p><img src="https://i.imgur.com/UZbJ3si.png" alt="" style="height:450px;" /></p>
</div><div>
<ul>
<li>4-y OS</li>
<li>90% v.s. 86%</li>
</ul>
</div></div>
</div></div>
<blockquote>
<p>TUTT, Andrew NJ, et al. Adjuvant olaparib for patients with BRCA1-or BRCA2-mutated breast cancer. New England Journal of Medicine, 2021, 384.25: 2394-2405.</p>
</blockquote>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="50" data-paginate="true" data-header="ALEXANDRA/IMpassion030" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="50" style="--paginate:true;--header:ALEXANDRA/IMpassion030;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>ALEXANDRA/IMpassion030</header>

<h2 id="alexandraimpassion030" tabindex="-1">ALEXANDRA/IMpassion030</h2>
<ul>
<li>atezolizumab to standard paclitaxel and ddAC ( w/o carboplatin)</li>
</ul>
<p><img src="https://i.imgur.com/GkMHzIr.png" alt="Figure:" style="width:1150px;" /></p>
<ul>
<li>Primary endpoint: iDFS in ITT population</li>
<li>Secondary endpoints: iDFS in PD-L1–positive and node-positive subpopulations, iDFS including second primary nonbreast invasive cancer, OS, RFI, DRFI, DFS</li>
</ul>
<blockquote>
<p>Ignatiadis. SABCS 2023. Abstr GS01-03.</p>
</blockquote>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="51" data-paginate="true" data-header="ALEXANDRA/IMpassion030" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="51" style="--paginate:true;--header:ALEXANDRA/IMpassion030;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>ALEXANDRA/IMpassion030</header>
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Atezo + Chemotherapy <br />(n = 1101)</th>
<th>Chemotherapy <br />(n = 1098)</th>
<th>HR (95% CI)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>iDFS events, ITT, n (%)</td>
<td>127 (11.5)</td>
<td>112 (10.2)</td>
<td>1.12 (0.87-1.45)</td>
<td>.37</td>
</tr>
<tr>
<td>iDFS events, PD-L1+, n/N (%)</td>
<td>77/785 (9.8)</td>
<td>73/782 (9.3)</td>
<td>1.03 (0.75-1.42)</td>
<td>NR</td>
</tr>
<tr>
<td>OS events, ITT, n (%)</td>
<td>61 (5.5)</td>
<td>49 (4.5)</td>
<td>1.20 (0.82-1.75)</td>
<td>NR</td>
</tr>
</tbody>
</table>
<p><img src="https://i.imgur.com/hsWtF67.png" alt="Figure:" style="height:400px;" /></p>
<blockquote>
<p>Loibl S, Schneeweiss A, Huober J, et al. Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Annals of Oncology. 2022;33(11):1149-1158. doi:10.1016/j.annonc.2022.07.1940</p>
</blockquote>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="52" data-paginate="true" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="52" style="--paginate:true;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<h2 id="clinical-questions-that-remain-brfor-early-stage-tnbc" tabindex="-1">Clinical Questions That Remain <br />for Early-Stage TNBC</h2>
<p><img src="https://i.imgur.com/xZ5sJka.png" alt="Figure:" style="width:1200px;" /></p>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="53" data-paginate="true" data-header="NeoPACT" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="53" style="--paginate:true;--header:NeoPACT;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>NeoPACT</header>

<h4 id="anthracycline-free-nac-pembro--carboplatin--docetaxel" tabindex="-1">anthracycline-free, NAC pembro + carboplatin + docetaxel?</h4>
<h2 id="neoadjuvant-phase-ii-study-of-pembrolizumab-and-carboplatin-plus-docetaxel-in-triple-negative-breast-cancer-neopact" tabindex="-1">Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer (NeoPACT)</h2>
<p><img src="./src/NeoPACT.svg" alt="title: NeoPACT" style="height:220px;" /></p>
<blockquote>
<p><a href="./src/NeoPACT.gv">Credit: Hsieh-Ting Lin, NeoPACT, CC-BY-NC-ND-2.0, via Graphviz</a></p>
</blockquote>
<h1 id="%E2%9D%A4%EF%B8%8F%F0%9F%A9%B9-%F0%9F%A7%9B" tabindex="-1"><img class="emoji" draggable="false" alt="❤️" src="https://cdn.jsdelivr.net/gh/jdecked/twemoji@14.1.2/assets/svg/2764.svg" data-marp-twemoji=""/><img class="emoji" draggable="false" alt="🩹" src="https://cdn.jsdelivr.net/gh/jdecked/twemoji@14.1.2/assets/svg/1fa79.svg" data-marp-twemoji=""/> <img class="emoji" draggable="false" alt="🧛" src="https://cdn.jsdelivr.net/gh/jdecked/twemoji@14.1.2/assets/svg/1f9db.svg" data-marp-twemoji=""/></h1>
<blockquote>
<p>MAYER, Ingrid A., et al. Randomized phase III postoperative trial of platinum-based chemotherapy versus capecitabine in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: ECOG-ACRIN EA1131. Journal of clinical oncology, 2021, 39.23: 2539.</p>
</blockquote>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="54" data-paginate="true" data-header="NeoPACT" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="54" style="--paginate:true;--header:NeoPACT;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>NeoPACT</header>
<h3 id="neopact-result-efs" tabindex="-1">NeoPACT: Result: EFS</h3>
<div class="free"><div>
<p><img src="https://i.imgur.com/CFC99Zv.png" alt="Figure:" style="height:550px;" /></p>
</div><div>
<ul>
<li>
<p>111pt</p>
</li>
<li>
<p>pCR: <strong>64(57%)</strong> -&gt; Adjuvant: 1 chemo, 1 pembro</p>
</li>
<li>
<p>RD:47 -&gt; Adjuvant: 38 chemo, 9 pembro</p>
</li>
<li>
<p>c.f. KEYNOTE-522:</p>
<ul>
<li>pCR: 64.8%, EFS 36 month 84.5%</li>
<li>in those without pCR, EFS rates
<ul>
<li>67.4%</li>
</ul>
</li>
<li>in those without pCR, EFS rates
<ul>
<li>67.4%</li>
</ul>
</li>
</ul>
</li>
</ul>
</div></div>
</div></div>
<blockquote>
<p>MAYER, Ingrid A., et al. Randomized phase III postoperative trial of platinum-based chemotherapy versus capecitabine in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: ECOG-ACRIN EA1131. Journal of clinical oncology, 2021, 39.23: 2539.</p>
</blockquote>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="55" data-paginate="true" data-header="Future directions" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="55" style="--paginate:true;--header:Future directions;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>Future directions</header>

<h2 id="future-directions" tabindex="-1">Future directions</h2>
<ul>
<li>AGO-B-041:
<ul>
<li>phase II trial,</li>
<li>NAC nab-paclitaxel(nP)/anthracycline + pembrolizumab</li>
<li>pCR: 66%.</li>
</ul>
</li>
<li>SWOG 2212 (SCARLET) will compare the
<ul>
<li>KEYNOTE-522 regimen with the NeoPACT regimen</li>
<li>with event-free survival as the primary endpoint.</li>
</ul>
</li>
<li>Alliance A012103 (OptimICE pCR; NCT05812807)
<ul>
<li>adjuvant pembrolizumab continuation vs discontinuation in stage II-III TNBC who achieved a pCR to neoadjuvant CT + CPI</li>
</ul>
</li>
</ul>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="56" data-paginate="true" data-header="Future directions" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="56" style="--paginate:true;--header:Future directions;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>Future directions</header>
<ul>
<li>OptimICE-RD (ASCENT-05)
<ul>
<li>phase III study of 1,514 patients with residual TNBC (ClinicalTrials.gov identifier: NCT05633654),</li>
<li>safety and efficacy of the addition of <strong>sacituzumab govitecan</strong> or capecitabine to pembrolizumab.</li>
</ul>
</li>
<li>TROPION-Breast-03
<ul>
<li><strong>datopotamab deruxtecan</strong> with or without <strong>durvalumab</strong> versus investigator's choice in patients with stage I-III TNBC without a pCR</li>
</ul>
</li>
</ul>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="57" data-paginate="true" data-header="Future directions" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="57" style="--paginate:true;--header:Future directions;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>Future directions</header>
<h1 id="pt-stage-ii-iii-tnbc-sp-nac-pembrolizumab-in-kfsyscc" tabindex="-1">Pt stage II, III TNBC s/p NAC pembrolizumab in KFSYSCC</h1>
<h1 id="%F0%9F%96%96%F0%9F%96%96%F0%9F%96%96%F0%9F%96%96%F0%9F%AA%A6" tabindex="-1"><img class="emoji" draggable="false" alt="🖖" src="https://cdn.jsdelivr.net/gh/jdecked/twemoji@14.1.2/assets/svg/1f596.svg" data-marp-twemoji=""/><img class="emoji" draggable="false" alt="🖖" src="https://cdn.jsdelivr.net/gh/jdecked/twemoji@14.1.2/assets/svg/1f596.svg" data-marp-twemoji=""/><img class="emoji" draggable="false" alt="🖖" src="https://cdn.jsdelivr.net/gh/jdecked/twemoji@14.1.2/assets/svg/1f596.svg" data-marp-twemoji=""/><img class="emoji" draggable="false" alt="🖖" src="https://cdn.jsdelivr.net/gh/jdecked/twemoji@14.1.2/assets/svg/1f596.svg" data-marp-twemoji=""/><img class="emoji" draggable="false" alt="🪦" src="https://cdn.jsdelivr.net/gh/jdecked/twemoji@14.1.2/assets/svg/1faa6.svg" data-marp-twemoji=""/></h1>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="58" data-paginate="true" data-header="Future directions" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="58" style="--paginate:true;--header:Future directions;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>Future directions</header>
<h2 id="case-06552566-%E5%8A%89-51-years" tabindex="-1">Case: 06552566-劉 (51 years)</h2>
<ul>
<li>Diagnosis: Left LABC</li>
<li>Histological Type: IDC</li>
<li>cTNM: cT(5cm)N2-3(f)M0</li>
<li>ER/PR/HER2: 3/0/1+</li>
<li>Ki-67: 60%</li>
<li>NG: 3</li>
<li>Neoadjuvant Therapy: Taxotere + Carboplatin x4 -&gt; ACx4 with Pembro x3</li>
<li>NAC Date: 2023/01/25 - 2023/06/21</li>
<li>Operation: WE+SLNB</li>
<li>OP Date: 2023/07/12</li>
<li>Post-op Staging: ypT0N0(sn0/1), pCR <img class="emoji" draggable="false" alt="🎉" src="https://cdn.jsdelivr.net/gh/jdecked/twemoji@14.1.2/assets/svg/1f389.svg" data-marp-twemoji=""/></li>
</ul>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="59" data-paginate="true" data-header="Future directions" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="59" style="--paginate:true;--header:Future directions;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>Future directions</header>
<h2 id="case-06706071-%E7%8E%8B-33-years" tabindex="-1">Case: 06706071-王 (33 years)</h2>
<ul>
<li>Diagnosis: Left LABC</li>
<li>Histological Type: IDC</li>
<li>cTNM: cT3N1M0</li>
<li>ER/PR/HER2: 0/0/0</li>
<li>Ki-67: 40%</li>
<li>NG: 3</li>
<li>Neoadjuvant Therapy: ACx4 -&gt; Cisplatin/Taxotere x4 with Pembro x6</li>
<li>NAC Date: 2023/03/20 - 2023/09/04</li>
<li>Operation: WE+SLNB+ALND</li>
<li>OP Date: 2023/10/13</li>
<li>Post-op Staging: ypT0N0, pCR <img class="emoji" draggable="false" alt="🎉" src="https://cdn.jsdelivr.net/gh/jdecked/twemoji@14.1.2/assets/svg/1f389.svg" data-marp-twemoji=""/></li>
</ul>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="60" data-paginate="true" data-header="Future directions" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="60" style="--paginate:true;--header:Future directions;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>Future directions</header>
<h2 id="case-06715205-%E5%BE%90-55-years" tabindex="-1">Case: 06715205-徐 (55 years)</h2>
<ul>
<li>Diagnosis: Left LABC</li>
<li>Histological Type: IDC</li>
<li>cTNM: cT3(5.7cm)N3M1(neck L5)</li>
<li>ER/PR/HER2: 0/0/1+</li>
<li>Ki-67: 80%</li>
<li>NG: 3</li>
<li>Neoadjuvant Therapy: Taxol/Carbo x4 -&gt; ACx4 with Pembro x8</li>
<li>NAC Date: 2023/04/19 - 2023/09/13</li>
<li>Operation: MRM</li>
<li>OP Date: 2023/10/11</li>
<li>Post-op Staging: ypT0/Tis ypN0, pCR <img class="emoji" draggable="false" alt="🎉" src="https://cdn.jsdelivr.net/gh/jdecked/twemoji@14.1.2/assets/svg/1f389.svg" data-marp-twemoji=""/></li>
</ul>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="61" data-paginate="true" data-header="Future directions" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="61" style="--paginate:true;--header:Future directions;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>Future directions</header>
<h2 id="case-05602289-%E8%97%8D-51-years" tabindex="-1">Case: 05602289-藍 (51 years)</h2>
<ul>
<li>Diagnosis: Right LABC</li>
<li>Histological Type: IDC</li>
<li>cTNM: cT3(6cm)N2(f)M0</li>
<li>ER/PR/HER2: 0/0/0</li>
<li>Ki-67: 74%</li>
<li>NG: 3</li>
<li>Neoadjuvant Therapy: Taxol/Carbo x4 -&gt; ACx4 with Pembro x8</li>
<li>NAC Date: 2023/03/06 - 2023/08/14</li>
<li>Operation: R't MRM</li>
<li>OP Date: 2023/09/16</li>
<li>Post-op Staging: ypT3(10.1cm)N3a(14/21)M0 <img class="emoji" draggable="false" alt="🦀" src="https://cdn.jsdelivr.net/gh/jdecked/twemoji@14.1.2/assets/svg/1f980.svg" data-marp-twemoji=""/> <img class="emoji" draggable="false" alt="😱" src="https://cdn.jsdelivr.net/gh/jdecked/twemoji@14.1.2/assets/svg/1f631.svg" data-marp-twemoji=""/></li>
</ul>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="62" data-paginate="true" data-header="Future directions" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="62" style="--paginate:true;--header:Future directions;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>Future directions</header>
<h2 id="case-06538409-%E8%94%A1-43-years" tabindex="-1">Case: 06538409-蔡 (43 years)</h2>
<ul>
<li>Diagnosis: Right LABC</li>
<li>Histological Type: IDC</li>
<li>cTNM: cT3(4.5 cm)N0M0</li>
<li>ER/PR/HER2: 0/0/0</li>
<li>Ki-67: 60%</li>
<li>NG: 3</li>
<li>Neoadjuvant Therapy: AC x4 -&gt; Taxotere + Cisplatin x3 with Pembro x6</li>
<li>NAC Date: 2022/12/13 - 2023/02/20</li>
<li>Operation: Deceased <img class="emoji" draggable="false" alt="🪦" src="https://cdn.jsdelivr.net/gh/jdecked/twemoji@14.1.2/assets/svg/1faa6.svg" data-marp-twemoji=""/></li>
<li>OP Date: NIL</li>
<li>Post-op Staging: NIL</li>
</ul>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="63" data-paginate="true" data-header="Future directions" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="63" style="--paginate:true;--header:Future directions;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>Future directions</header>
<div style="width: 1200px; height: 700px; overflow: hidden;">
<iframe src="https://docs.google.com/spreadsheets/d/e/2PACX-1vSOf1x9zSvUCn2aNLo8xOGKSRu7N21qE6XQ7eoZQ3zbLcG-wfWC5fdnBIPwWOpOEjfd3TUgZN0ercAZ/pubhtml?gid=1947694028&amp;single=true&amp;widget=true&amp;headers=false"
    width="750" height="500" style="transform: scale(1.5); transform-origin: 0 0; border: none;"></iframe>
</div>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="64" data-paginate="true" data-header="Future directions" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="64" style="--paginate:true;--header:Future directions;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<header>Future directions</header>
<h1 is="marp-h1" data-auto-scaling id="summary" tabindex="-1">Summary</h1>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section data-paginate="true" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="65" style="--paginate:true;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70" data-marpit-advanced-background="background"><div data-marpit-advanced-background-container="true" data-marpit-advanced-background-direction="horizontal"><figure style="background-image:url(&quot;https://i.imgur.com/U5MMXDY.jpg&quot;);background-size:auto 650px;"></figure></div></section></foreignObject><foreignObject width="1280" height="720"><section id="65" data-paginate="true" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="65" style="--paginate:true;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70" data-marpit-advanced-background="content">
<p><br /> <br /> <br /> <br /> <br /> <br /> <br /><br />
<br /> <br /> <br /> <br /> <br /> <br /> <br /></p>
<h2 id="esmobr-2023-12" tabindex="-1">  ESMO<br />  2023-12</h2>
</section>
</foreignObject><foreignObject width="1280" height="720" data-marpit-advanced-background="pseudo"><section data-paginate="true" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="65" style="" data-marpit-pagination-total="70" data-marpit-advanced-background="pseudo"></section></foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="66" data-paginate="true" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="66" style="--paginate:true;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<h2 id="hightlight-of-esmo-2023-etnbc" tabindex="-1">Hightlight of ESMO 2023 ETNBC</h2>
<ul>
<li>Pembrolizumab should be administered
<ul>
<li>every 3 weeks throughout the neoadjuvant phase [I, A] and</li>
<li>for nine 3-week cycles during the adjuvant phase,</li>
<li>regardless of pCR status [I, A; ESMO-MCBS v1.1 score: A].</li>
</ul>
</li>
<li>An ICI should not be given solely as adjuvant therapy without prior neoadjuvant ICI treatment</li>
<li>For cT1c-4 N0, or any N-positive TNBC, neoadjuvant treatment is preferred</li>
<li>The combination of olaparib and capecitabine in patients with gBRCAm should not be used</li>
</ul>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="67" data-paginate="true" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="67" style="--paginate:true;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<h3 id="back-to-our-current-tnbc-guideline" tabindex="-1">Back to our current TNBC guideline</h3>
<h2 id="kfsyscc-early-tnbc-treatment-guideline-2024" tabindex="-1">KFSYSCC early TNBC treatment guideline 2024?</h2>
<p><img src="./src/KFSYSCC_early_TNBC_treatment_guideline.svg" alt="title: KFSYSCC_early_TNBC_treatment_guideline" style="height:450px;" /></p>
<blockquote>
<p><a href="./src/KFSYSCC_early_TNBC_treatment_guideline.gv">KFSYSCC_early_TNBC_treatment_guideline Ⓒ Hsieh-Ting Lin</a></p>
</blockquote>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="68" data-paginate="true" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="68" style="--paginate:true;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70">
<h2 id="take-home-messages" tabindex="-1">Take Home Messages</h2>
<div class="free"><div>
<ol>
<li>TNBC remains the worse outcomes compared with ER–positive and HER2-positive, largely attributed to limited treatment options.</li>
<li>Anthracycline and taxane-based chemotherapy regimens remain the standard of care for high-risk TNBC, with the addition of ICPis for stage II and III TNBC.</li>
<li>The KEYNOTE-522 regimen represents a ceiling treatment; it is very effective, but also very toxic</li>
<li>irAE is critical, avoiding severe life-threatening events.</li>
</ol>
</div><div>
<p><img src="https://i.imgur.com/mQWjUDZ.png" alt="Figure:" style="height:350px;" /></p>
</div></div>
</div></div>
<h2 id="%F0%9F%99%8B-question-who-should-be-treated-with-the-keynote-522-regimen" tabindex="-1"><img class="emoji" draggable="false" alt="🙋" src="https://cdn.jsdelivr.net/gh/jdecked/twemoji@14.1.2/assets/svg/1f64b.svg" data-marp-twemoji=""/> Question: Who Should Be Treated With the KEYNOTE-522 Regimen?</h2>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section data-paginate="true" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="69" style="--paginate:true;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;--marpit-advanced-background-split:55%;" data-marpit-pagination-total="70" data-marpit-advanced-background="background" data-marpit-advanced-background-split="right"><div data-marpit-advanced-background-container="true" data-marpit-advanced-background-direction="horizontal"><figure style="background-image:url(&quot;https://media.tenor.com/Q-OWuADzjMQAAAAC/burp-leo.gif&quot;);background-size:auto 730px;"></figure></div></section></foreignObject><foreignObject width="45%" height="720"><section id="69" data-paginate="true" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="69" style="--paginate:true;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;--marpit-advanced-background-split:55%;" data-marpit-pagination-total="70" data-marpit-advanced-background="content" data-marpit-advanced-background-split="right">
<h1 id="thank-you-for-your-time-and-attention" tabindex="-1">Thank you for your time and attention</h1>
<h2 id="merry-christmas-%F0%9F%8E%84brand-happy-new-year" tabindex="-1"><em>Merry Christmas <img class="emoji" draggable="false" alt="🎄" src="https://cdn.jsdelivr.net/gh/jdecked/twemoji@14.1.2/assets/svg/1f384.svg" data-marp-twemoji=""/><br />and Happy New Year</em></h2>
</section>
</foreignObject><foreignObject width="1280" height="720" data-marpit-advanced-background="pseudo"><section data-paginate="true" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="69" style="" data-marpit-pagination-total="70" data-marpit-advanced-background="pseudo" data-marpit-advanced-background-split="right"></section></foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="70" data-paginate="true" data-theme="ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g" data-marpit-pagination="70" style="--paginate:true;--theme:ynrafoq0r6nclzusz6kis8ttqqtf4m1w9xyonbvky1g;" data-marpit-pagination-total="70"></section>
<script>!function(){"use strict";const t={h1:{proto:()=>HTMLHeadingElement,attrs:{role:"heading","aria-level":"1"},style:"display: block; font-size: 2em; margin-block-start: 0.67em; margin-block-end: 0.67em; margin-inline-start: 0px; margin-inline-end: 0px; font-weight: bold;"},h2:{proto:()=>HTMLHeadingElement,attrs:{role:"heading","aria-level":"2"},style:"display: block; font-size: 1.5em; margin-block-start: 0.83em; margin-block-end: 0.83em; margin-inline-start: 0px; margin-inline-end: 0px; font-weight: bold;"},h3:{proto:()=>HTMLHeadingElement,attrs:{role:"heading","aria-level":"3"},style:"display: block; font-size: 1.17em; margin-block-start: 1em; margin-block-end: 1em; margin-inline-start: 0px; margin-inline-end: 0px; font-weight: bold;"},h4:{proto:()=>HTMLHeadingElement,attrs:{role:"heading","aria-level":"4"},style:"display: block; margin-block-start: 1.33em; margin-block-end: 1.33em; margin-inline-start: 0px; margin-inline-end: 0px; font-weight: bold;"},h5:{proto:()=>HTMLHeadingElement,attrs:{role:"heading","aria-level":"5"},style:"display: block; font-size: 0.83em; margin-block-start: 1.67em; margin-block-end: 1.67em; margin-inline-start: 0px; margin-inline-end: 0px; font-weight: bold;"},h6:{proto:()=>HTMLHeadingElement,attrs:{role:"heading","aria-level":"6"},style:"display: block; font-size: 0.67em; margin-block-start: 2.33em; margin-block-end: 2.33em; margin-inline-start: 0px; margin-inline-end: 0px; font-weight: bold;"},span:{proto:()=>HTMLSpanElement},pre:{proto:()=>HTMLElement,style:"display: block; font-family: monospace; white-space: pre; margin: 1em 0; --marp-auto-scaling-white-space: pre;"}},e="data-marp-auto-scaling-wrapper",i="data-marp-auto-scaling-svg",n="data-marp-auto-scaling-container";class s extends HTMLElement{constructor(){super(),this.svgPreserveAspectRatio="xMinYMid meet";const t=t=>([e])=>{const{width:i,height:n}=e.contentRect;this[t]={width:i,height:n},this.updateSVGRect()};this.attachShadow({mode:"open"}),this.containerObserver=new ResizeObserver(t("containerSize")),this.wrapperObserver=new ResizeObserver(((...e)=>{t("wrapperSize")(...e),this.flushSvgDisplay()}))}static get observedAttributes(){return["data-downscale-only"]}connectedCallback(){var t,s,o,r,a;this.shadowRoot.innerHTML=`\n<style>\n  svg[${i}] { display: block; width: 100%; height: auto; vertical-align: top; }\n  span[${n}] { display: table; white-space: var(--marp-auto-scaling-white-space, nowrap); width: max-content; }\n</style>\n<div ${e}>\n  <svg part="svg" ${i}>\n    <foreignObject><span ${n}><slot></slot></span></foreignObject>\n  </svg>\n</div>\n    `.split(/\n\s*/).join(""),this.wrapper=null!==(t=this.shadowRoot.querySelector(`div[${e}]`))&&void 0!==t?t:void 0;const l=this.svg;this.svg=null!==(o=null===(s=this.wrapper)||void 0===s?void 0:s.querySelector(`svg[${i}]`))&&void 0!==o?o:void 0,this.svg!==l&&(this.svgComputedStyle=this.svg?window.getComputedStyle(this.svg):void 0),this.container=null!==(a=null===(r=this.svg)||void 0===r?void 0:r.querySelector(`span[${n}]`))&&void 0!==a?a:void 0,this.observe()}disconnectedCallback(){this.svg=void 0,this.svgComputedStyle=void 0,this.wrapper=void 0,this.container=void 0,this.observe()}attributeChangedCallback(){this.observe()}flushSvgDisplay(){const{svg:t}=this;t&&(t.style.display="inline",requestAnimationFrame((()=>{t.style.display=""})))}observe(){this.containerObserver.disconnect(),this.wrapperObserver.disconnect(),this.wrapper&&this.wrapperObserver.observe(this.wrapper),this.container&&this.containerObserver.observe(this.container),this.svgComputedStyle&&this.observeSVGStyle(this.svgComputedStyle)}observeSVGStyle(t){const e=()=>{const i=(()=>{const e=t.getPropertyValue("--preserve-aspect-ratio");if(e)return e.trim();return`x${(({textAlign:t,direction:e})=>{if(t.endsWith("left"))return"Min";if(t.endsWith("right"))return"Max";if("start"===t||"end"===t){let i="rtl"===e;return"end"===t&&(i=!i),i?"Max":"Min"}return"Mid"})(t)}YMid meet`})();i!==this.svgPreserveAspectRatio&&(this.svgPreserveAspectRatio=i,this.updateSVGRect()),t===this.svgComputedStyle&&requestAnimationFrame(e)};e()}updateSVGRect(){var t,e,i,n,s,o,r;let a=Math.ceil(null!==(e=null===(t=this.containerSize)||void 0===t?void 0:t.width)&&void 0!==e?e:0);const l=Math.ceil(null!==(n=null===(i=this.containerSize)||void 0===i?void 0:i.height)&&void 0!==n?n:0);void 0!==this.dataset.downscaleOnly&&(a=Math.max(a,null!==(o=null===(s=this.wrapperSize)||void 0===s?void 0:s.width)&&void 0!==o?o:0));const c=null===(r=this.svg)||void 0===r?void 0:r.querySelector(":scope > foreignObject");if(null==c||c.setAttribute("width",`${a}`),null==c||c.setAttribute("height",`${l}`),this.svg&&(this.svg.setAttribute("viewBox",`0 0 ${a} ${l}`),this.svg.setAttribute("preserveAspectRatio",this.svgPreserveAspectRatio),this.svg.style.height=a<=0||l<=0?"0":""),this.container){const t=this.svgPreserveAspectRatio.toLowerCase();this.container.style.marginLeft=t.startsWith("xmid")||t.startsWith("xmax")?"auto":"0",this.container.style.marginRight=t.startsWith("xmi")?"auto":"0"}}}const o=(t,{attrs:e={},style:i})=>class extends t{constructor(...t){super(...t);for(const[t,i]of Object.entries(e))this.hasAttribute(t)||this.setAttribute(t,i);this.attachShadow({mode:"open"})}static get observedAttributes(){return["data-auto-scaling"]}connectedCallback(){this._update()}attributeChangedCallback(){this._update()}_update(){const t=i?`<style>:host { ${i} }</style>`:"";let e="<slot></slot>";const{autoScaling:n}=this.dataset;if(void 0!==n){e=`<marp-auto-scaling exportparts="svg:auto-scaling" ${"downscale-only"===n?"data-downscale-only":""}>${e}</marp-auto-scaling>`}this.shadowRoot.innerHTML=t+e}};let r;const a=Symbol();let l;const c="marpitSVGPolyfill:setZoomFactor,",d=Symbol(),g=Symbol();const h=()=>{const t="Apple Computer, Inc."===navigator.vendor,e=t?[u]:[],i={then:e=>(t?(async()=>{if(void 0===l){const t=document.createElement("canvas");t.width=10,t.height=10;const e=t.getContext("2d"),i=new Image(10,10),n=new Promise((t=>{i.addEventListener("load",(()=>t()))}));i.crossOrigin="anonymous",i.src="data:image/svg+xml;charset=utf8,%3Csvg%20xmlns%3D%22http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%22%20width%3D%2210%22%20height%3D%2210%22%20viewBox%3D%220%200%201%201%22%3E%3CforeignObject%20width%3D%221%22%20height%3D%221%22%20requiredExtensions%3D%22http%3A%2F%2Fwww.w3.org%2F1999%2Fxhtml%22%3E%3Cdiv%20xmlns%3D%22http%3A%2F%2Fwww.w3.org%2F1999%2Fxhtml%22%20style%3D%22width%3A%201px%3B%20height%3A%201px%3B%20background%3A%20red%3B%20position%3A%20relative%22%3E%3C%2Fdiv%3E%3C%2FforeignObject%3E%3C%2Fsvg%3E",await n,e.drawImage(i,0,0),l=e.getImageData(5,5,1,1).data[3]<128}return l})().then((t=>{null==e||e(t?[u]:[])})):null==e||e([]),i)};return Object.assign(e,i)};let p,m;function u(t){const e="object"==typeof t&&t.target||document,i="object"==typeof t?t.zoom:t;window[g]||(Object.defineProperty(window,g,{configurable:!0,value:!0}),document.body.style.zoom=1.0001,document.body.offsetHeight,document.body.style.zoom=1,window.addEventListener("message",(({data:t,origin:e})=>{if(e===window.origin)try{if(t&&"string"==typeof t&&t.startsWith(c)){const[,e]=t.split(","),i=Number.parseFloat(e);Number.isNaN(i)||(m=i)}}catch(t){console.error(t)}})));let n=!1;Array.from(e.querySelectorAll("svg[data-marpit-svg]"),(t=>{var e,s,o,r;t.style.transform||(t.style.transform="translateZ(0)");const a=i||m||t.currentScale||1;p!==a&&(p=a,n=a);const l=t.getBoundingClientRect(),{length:c}=t.children;for(let i=0;i<c;i+=1){const n=t.children[i];if(n.getScreenCTM){const t=n.getScreenCTM();if(t){const i=null!==(s=null===(e=n.x)||void 0===e?void 0:e.baseVal.value)&&void 0!==s?s:0,c=null!==(r=null===(o=n.y)||void 0===o?void 0:o.baseVal.value)&&void 0!==r?r:0,d=n.children.length;for(let e=0;e<d;e+=1){const s=n.children[e];if("SECTION"===s.tagName){const{style:e}=s;e.transformOrigin||(e.transformOrigin=`${-i}px ${-c}px`),e.transform=`scale(${a}) matrix(${t.a}, ${t.b}, ${t.c}, ${t.d}, ${t.e-l.left}, ${t.f-l.top}) translateZ(0.0001px)`;break}}}}}})),!1!==n&&Array.from(e.querySelectorAll("iframe"),(({contentWindow:t})=>{null==t||t.postMessage(`${c}${n}`,"null"===window.origin?"*":window.origin)}))}function v({once:t=!1,target:e=document}={}){const i=function(t=document){if(t[d])return t[d];let e=!0;const i=()=>{e=!1,delete t[d]};Object.defineProperty(t,d,{configurable:!0,value:i});let n=[],s=!1;(async()=>{try{n=await h()}finally{s=!0}})();const o=()=>{for(const e of n)e({target:t});s&&0===n.length||e&&window.requestAnimationFrame(o)};return o(),i}(e);return t?(i(),()=>{}):i}p=1,m=void 0;const b=Symbol(),w=(e=document)=>{if("undefined"==typeof window)throw new Error("Marp Core's browser script is valid only in browser context.");if(((e=document)=>{const i=window[a];i||customElements.define("marp-auto-scaling",s);for(const n of Object.keys(t)){const s=`marp-${n}`,a=t[n].proto();null!=r||(r=!!document.createElement("div",{is:"marp-auto-scaling"}).outerHTML.startsWith("<div is")),r&&a!==HTMLElement?i||customElements.define(s,o(a,{style:t[n].style}),{extends:n}):(i||customElements.define(s,o(HTMLElement,t[n])),e.querySelectorAll(`${n}[is="${s}"]`).forEach((t=>{t.outerHTML=t.outerHTML.replace(new RegExp(`^<${n}`,"i"),`<${s}`).replace(new RegExp(`</${n}>$`,"i"),`</${s}>`)})))}window[a]=!0})(e),e[b])return e[b];const i=v({target:e}),n=()=>{i(),delete e[b]},l=Object.assign(n,{cleanup:n,update:()=>w(e)});return Object.defineProperty(e,b,{configurable:!0,value:l}),l},y=document.currentScript;w(y?y.getRootNode():document)}();
</script></foreignObject></svg></div><div class="bespoke-marp-note" data-index="1" tabindex="0"><p>TODO: meme 驚嚇的貓貓</p></div><div class="bespoke-marp-note" data-index="13" tabindex="0"><p>![Figure: height:350px](https://i.imgur.com/QFToz5v.png)</p></div><div class="bespoke-marp-note" data-index="18" tabindex="0"><p>The addition of a platinum-based chemotherapy, such as carboplatin, to NAC regimens for TNBC has been studied in several randomized trials. Adding carboplatin to the paclitaxel- and anthracycline-based regimen increased the pCR rates in patients with TNBC.</p><p>Carboplatin did not improve pathologic complete response in the HER2-positive group.</p></div><div class="bespoke-marp-note" data-index="19" tabindex="0"><p>TODO:</p><p>had a significantly better 3-year DFS (HR, 0.56; 95% CI, 0.34 to 0.93; P = .024) and distant disease-free survival (DDFS; HR, 0.50; 95% CI, 0.29 to 0.86; P = .013).19</p><p>Results: After a median follow-up of 47.3 months (range 1.7-62.8) overall no significant difference in DFS was seen with PMCb vs PM (HR = 0.83 [95%CI 0.58-1.20]; p = 0.327). However, Pts with TNBC had a significantly better DFS (HR = 0.56 [95%CI 0.34-0.93]; p = 0.024) and DDFS (HR = 0.50 [95%CI 0.29-0.86]; p = 0.013) when treated with PMCb. No difference was seen in pts with HER2+ disease (DFS HR = 1.34 [95%CI 0.77-2.34]; p = 0.295; interaction test p = 0.022 and DDFS HR = 1.56 [95% CI 0.86-2.83]; p = 0.145; interaction test p = 0.006). A trend towards a better OS was observed in pts with TNBC (HR = 0.60 [95%CI 0.32-1.12]; p = 0.110). OS was not different between the two arms, neither overall (HR = 0.72 [95%CI 0.43-1.21]; p = 0.223) nor in HER2+ disease (HR = 1.13 [95%CI 0.44-2.93]; p = 0.800). Multivariable analysis comfirms that pCR (pCR vs no pCR) independently predicted DFS (HR = 0.23, p &lt; 0.001), DDFS (HR = 0.21, p &lt; 0.001), and OS (HR = 0.29, p = 0.002).</p><p>Conclusions: Long-term survival analysis supports the neoadjuvant use of Cb in TNBC. The value of pCR as a strong predictor of DFS and OS was confirmed.</p></div><div class="bespoke-marp-note" data-index="22" tabindex="0"><p>地球超人</p></div><div class="bespoke-marp-note" data-index="24" tabindex="0"><p>mechanism</p></div><div class="bespoke-marp-note" data-index="33" tabindex="0"><p>&lt;!-- pCR rate result</p><p></p><p>![Figure: height:600px](https://i.imgur.com/MNLbG7A.png)</p><p></p><p>&gt; 64.8% vs 51.2%</p><p></p><p>---</p><p>graphical result table</p></div><div class="bespoke-marp-note" data-index="34" tabindex="0"><p>subgroup</p></div><div class="bespoke-marp-note" data-index="35" tabindex="0"><p>36 month EFS</p></div><div class="bespoke-marp-note" data-index="37" tabindex="0"><p>again subgroup 2022</p></div><div class="bespoke-marp-note" data-index="54" tabindex="0"><p>### Ohter findings: sTIL as biomarkers</p><p></p><p>![Figure: height:450px](https://i.imgur.com/tOFEedG.png)</p><p></p><p>&gt; MAYER, Ingrid A., et al. Randomized phase III postoperative trial of platinum-based chemotherapy versus capecitabine in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: ECOG-ACRIN EA1131. Journal of clinical oncology, 2021, 39.23: 2539.</p><p></p><p>---</p></div><div class="bespoke-marp-note" data-index="55" tabindex="0"><p>Should We Use Carboplatin?</p><p>Should We Use Dose-Dense AC?</p><p>Is There a Role for Other ICIs?</p><p>Is Adjuvant Pembrolizumab After pCR Needed?</p><p>What Adjuvant Therapies Should Be Given to Patients With Residual Disease?</p><p>How Should Adjuvant Radiotherapy Be Sequenced With Adjuvant Systemic Therapies?</p></div><div class="bespoke-marp-note" data-index="68" tabindex="0"><p>![emojik RLQ height:300px](https://emojik.vercel.app/s/☀️_😎?size=256)</p></div><div class="bespoke-marp-note" data-index="69" tabindex="0"><p>- The EFS subgroup analysis demonstrated benefit regardless of nodal status</p><p>- However, patients with stage II disease appeared to have a lesser improvement in pCR compared with those with stage III</p><p>- pCR rate improved by 7.8%–11% in stage II, but 24.6%–25.6% in stage III).19</p><p>- All patients sustaining pCR had high EFS rates, irrespective of receiving neoadjuvant pembrolizumab.</p><p></p><p>&gt; Santa-Maria CA, O’Donnell M, Nunes R, Wright JL, Stearns V. Integrating Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Practical Evidence-Based Considerations. J Natl Compr Canc Netw. 2022;20(7):738-744. doi:10.6004/jnccn.2022.7025</p></div><script>/*!! License: https://unpkg.com/@marp-team/marp-cli@3.3.1/lib/bespoke.js.LICENSE.txt */
!function(){"use strict";function e(e){return e&&e.__esModule&&Object.prototype.hasOwnProperty.call(e,"default")?e.default:e}var t={from:function(e,t){var n,r=1===(e.parent||e).nodeType?e.parent||e:document.querySelector(e.parent||e),o=[].filter.call("string"==typeof e.slides?r.querySelectorAll(e.slides):e.slides||r.children,(function(e){return"SCRIPT"!==e.nodeName})),i={},a=function(e,t){return(t=t||{}).index=o.indexOf(e),t.slide=e,t},s=function(e,t){i[e]=(i[e]||[]).filter((function(e){return e!==t}))},l=function(e,t){return(i[e]||[]).reduce((function(e,n){return e&&!1!==n(t)}),!0)},c=function(e,t){o[e]&&(n&&l("deactivate",a(n,t)),n=o[e],l("activate",a(n,t)))},d=function(e,t){var r=o.indexOf(n)+e;l(e>0?"next":"prev",a(n,t))&&c(r,t)},u={off:s,on:function(e,t){return(i[e]||(i[e]=[])).push(t),s.bind(null,e,t)},fire:l,slide:function(e,t){if(!arguments.length)return o.indexOf(n);l("slide",a(o[e],t))&&c(e,t)},next:d.bind(null,1),prev:d.bind(null,-1),parent:r,slides:o,destroy:function(e){l("destroy",a(n,e)),i={}}};return(t||[]).forEach((function(e){e(u)})),n||c(0),u}},n=e(t);const r=document.body,o=(...e)=>history.replaceState(...e),i="presenter",a="next",s=["",i,a],l="bespoke-marp-",c=`data-${l}`,d=(e,{protocol:t,host:n,pathname:r,hash:o}=location)=>{const i=e.toString();return`${t}//${n}${r}${i?"?":""}${i}${o}`},u=()=>r.dataset.bespokeView,f=e=>new URLSearchParams(location.search).get(e),m=(e,t={})=>{var n;const r={location,setter:o,...t},i=new URLSearchParams(r.location.search);for(const t of Object.keys(e)){const n=e[t];"string"==typeof n?i.set(t,n):i.delete(t)}try{r.setter({...null!==(n=window.history.state)&&void 0!==n?n:{}},"",d(i,r.location))}catch(e){console.error(e)}},g=(()=>{const e="bespoke-marp";try{return localStorage.setItem(e,e),localStorage.removeItem(e),!0}catch(e){return!1}})(),p=e=>{try{return localStorage.getItem(e)}catch(e){return null}},v=(e,t)=>{try{return localStorage.setItem(e,t),!0}catch(e){return!1}},h=e=>{try{return localStorage.removeItem(e),!0}catch(e){return!1}},y=(e,t)=>{const n="aria-hidden";t?e.setAttribute(n,"true"):e.removeAttribute(n)},b=e=>{e.parent.classList.add(`${l}parent`),e.slides.forEach((e=>e.classList.add(`${l}slide`))),e.on("activate",(t=>{const n=`${l}active`,r=t.slide,o=r.classList,i=!o.contains(n);if(e.slides.forEach((e=>{e.classList.remove(n),y(e,!0)})),o.add(n),y(r,!1),i){const e=`${n}-ready`;o.add(e),document.body.clientHeight,o.remove(e)}}))},w=e=>{let t=0,n=0;Object.defineProperty(e,"fragments",{enumerable:!0,value:e.slides.map((e=>[null,...e.querySelectorAll("[data-marpit-fragment]")]))});const r=r=>void 0!==e.fragments[t][n+r],o=(r,o)=>{t=r,n=o,e.fragments.forEach(((e,t)=>{e.forEach(((e,n)=>{if(null==e)return;const i=t<r||t===r&&n<=o;e.setAttribute(`${c}fragment`,(i?"":"in")+"active");const a=`${c}current-fragment`;t===r&&n===o?e.setAttribute(a,"current"):e.removeAttribute(a)}))})),e.fragmentIndex=o;const i={slide:e.slides[r],index:r,fragments:e.fragments[r],fragmentIndex:o};e.fire("fragment",i)};e.on("next",(({fragment:i=!0})=>{if(i){if(r(1))return o(t,n+1),!1;const i=t+1;e.fragments[i]&&o(i,0)}else{const r=e.fragments[t].length;if(n+1<r)return o(t,r-1),!1;const i=e.fragments[t+1];i&&o(t+1,i.length-1)}})),e.on("prev",(({fragment:i=!0})=>{if(r(-1)&&i)return o(t,n-1),!1;const a=t-1;e.fragments[a]&&o(a,e.fragments[a].length-1)})),e.on("slide",(({index:t,fragment:n})=>{let r=0;if(void 0!==n){const o=e.fragments[t];if(o){const{length:e}=o;r=-1===n?e-1:Math.min(Math.max(n,0),e-1)}}o(t,r)})),o(0,0)},x=document,k=()=>!(!x.fullscreenEnabled&&!x.webkitFullscreenEnabled),$=()=>!(!x.fullscreenElement&&!x.webkitFullscreenElement),E=e=>{e.fullscreen=()=>{k()&&(async()=>{return $()?null===(e=x.exitFullscreen||x.webkitExitFullscreen)||void 0===e?void 0:e.call(x):((e=x.body)=>{var t;return null===(t=e.requestFullscreen||e.webkitRequestFullscreen)||void 0===t?void 0:t.call(e)})();var e})()},document.addEventListener("keydown",(t=>{"f"!==t.key&&"F11"!==t.key||t.altKey||t.ctrlKey||t.metaKey||!k()||(e.fullscreen(),t.preventDefault())}))},L=`${l}inactive`,S=(e=2e3)=>({parent:t,fire:n})=>{const r=t.classList,o=e=>n(`marp-${e?"":"in"}active`);let i;const a=()=>{i&&clearTimeout(i),i=setTimeout((()=>{r.add(L),o()}),e),r.contains(L)&&(r.remove(L),o(!0))};for(const e of["mousedown","mousemove","touchend"])document.addEventListener(e,a);setTimeout(a,0)},P=["AUDIO","BUTTON","INPUT","SELECT","TEXTAREA","VIDEO"],_=e=>{e.parent.addEventListener("keydown",(e=>{if(!e.target)return;const t=e.target;(P.includes(t.nodeName)||"true"===t.contentEditable)&&e.stopPropagation()}))},T=e=>{window.addEventListener("load",(()=>{for(const t of e.slides){const e=t.querySelector("marp-auto-scaling, [data-auto-scaling], [data-marp-fitting]");t.setAttribute(`${c}load`,e?"":"hideable")}}))},I=({interval:e=250}={})=>t=>{document.addEventListener("keydown",(e=>{if(" "===e.key&&e.shiftKey)t.prev();else if("ArrowLeft"===e.key||"ArrowUp"===e.key||"PageUp"===e.key)t.prev({fragment:!e.shiftKey});else if(" "!==e.key||e.shiftKey)if("ArrowRight"===e.key||"ArrowDown"===e.key||"PageDown"===e.key)t.next({fragment:!e.shiftKey});else if("End"===e.key)t.slide(t.slides.length-1,{fragment:-1});else{if("Home"!==e.key)return;t.slide(0)}else t.next();e.preventDefault()}));let n,r,o=0;t.parent.addEventListener("wheel",(i=>{let a=!1;const s=(e,t)=>{e&&(a=a||((e,t)=>((e,t)=>{const n="X"===t?"Width":"Height";return e[`client${n}`]<e[`scroll${n}`]})(e,t)&&((e,t)=>{const{overflow:n}=e,r=e[`overflow${t}`];return"auto"===n||"scroll"===n||"auto"===r||"scroll"===r})(getComputedStyle(e),t))(e,t)),(null==e?void 0:e.parentElement)&&s(e.parentElement,t)};if(0!==i.deltaX&&s(i.target,"X"),0!==i.deltaY&&s(i.target,"Y"),a)return;i.preventDefault();const l=Math.sqrt(i.deltaX**2+i.deltaY**2);if(void 0!==i.wheelDelta){if(void 0===i.webkitForce&&Math.abs(i.wheelDelta)<40)return;if(i.deltaMode===i.DOM_DELTA_PIXEL&&l<4)return}else if(i.deltaMode===i.DOM_DELTA_PIXEL&&l<12)return;r&&clearTimeout(r),r=setTimeout((()=>{n=0}),e);const c=Date.now()-o<e,d=l<=n;if(n=l,c||d)return;let u;(i.deltaX>0||i.deltaY>0)&&(u="next"),(i.deltaX<0||i.deltaY<0)&&(u="prev"),u&&(t[u](),o=Date.now())}))},M=(e=`.${l}osc`)=>{const t=document.querySelector(e);if(!t)return()=>{};const n=(e,n)=>{t.querySelectorAll(`[${c}osc=${JSON.stringify(e)}]`).forEach(n)};return k()||n("fullscreen",(e=>e.style.display="none")),g||n("presenter",(e=>{e.disabled=!0,e.title="Presenter view is disabled due to restricted localStorage."})),e=>{t.addEventListener("click",(t=>{if(t.target instanceof HTMLElement){const{bespokeMarpOsc:n}=t.target.dataset;n&&t.target.blur();const r={fragment:!t.shiftKey};"next"===n?e.next(r):"prev"===n?e.prev(r):"fullscreen"===n?null==e||e.fullscreen():"presenter"===n&&e.openPresenterView()}})),e.parent.appendChild(t),e.on("activate",(({index:t})=>{n("page",(n=>n.textContent=`Page ${t+1} of ${e.slides.length}`))})),e.on("fragment",(({index:t,fragments:r,fragmentIndex:o})=>{n("prev",(e=>e.disabled=0===t&&0===o)),n("next",(n=>n.disabled=t===e.slides.length-1&&o===r.length-1))})),e.on("marp-active",(()=>y(t,!1))),e.on("marp-inactive",(()=>y(t,!0))),k()&&(e=>{for(const t of["","webkit"])x.addEventListener(t+"fullscreenchange",e)})((()=>n("fullscreen",(e=>e.classList.toggle("exit",k()&&$())))))}},O=e=>{window.addEventListener("message",(t=>{if(t.origin!==window.origin)return;const[n,r]=t.data.split(":");if("navigate"===n){const[t,n]=r.split(",");let o=Number.parseInt(t,10),i=Number.parseInt(n,10)+1;i>=e.fragments[o].length&&(o+=1,i=0),e.slide(o,{fragment:i})}}))};var A=["area","base","br","col","command","embed","hr","img","input","keygen","link","meta","param","source","track","wbr"];let C=e=>String(e).replace(/[&<>"']/g,(e=>`&${D[e]};`)),D={"&":"amp","<":"lt",">":"gt",'"':"quot","'":"apos"},N="dangerouslySetInnerHTML",B={className:"class",htmlFor:"for"},q={};function K(e,t){let n=[],r="";t=t||{};for(let e=arguments.length;e-- >2;)n.push(arguments[e]);if("function"==typeof e)return t.children=n.reverse(),e(t);if(e){if(r+="<"+e,t)for(let e in t)!1!==t[e]&&null!=t[e]&&e!==N&&(r+=` ${B[e]?B[e]:C(e)}="${C(t[e])}"`);r+=">"}if(-1===A.indexOf(e)){if(t[N])r+=t[N].__html;else for(;n.length;){let e=n.pop();if(e)if(e.pop)for(let t=e.length;t--;)n.push(e[t]);else r+=!0===q[e]?e:C(e)}r+=e?`</${e}>`:""}return q[r]=!0,r}const j=({children:e})=>K(null,null,...e),F=`${l}presenter-`,V={container:`${F}container`,dragbar:`${F}dragbar-container`,next:`${F}next`,nextContainer:`${F}next-container`,noteContainer:`${F}note-container`,noteWrapper:`${F}note-wrapper`,noteButtons:`${F}note-buttons`,infoContainer:`${F}info-container`,infoPage:`${F}info-page`,infoPageText:`${F}info-page-text`,infoPagePrev:`${F}info-page-prev`,infoPageNext:`${F}info-page-next`,noteButtonsBigger:`${F}note-bigger`,noteButtonsSmaller:`${F}note-smaller`,infoTime:`${F}info-time`,infoTimer:`${F}info-timer`},U=e=>{const{title:t}=document;document.title="[Presenter view]"+(t?` - ${t}`:"");const n={},r=e=>(n[e]=n[e]||document.querySelector(`.${e}`),n[e]);document.body.appendChild((e=>{const t=document.createElement("div");return t.className=V.container,t.appendChild(e),t.insertAdjacentHTML("beforeend",K(j,null,K("div",{class:V.nextContainer},K("iframe",{class:V.next,src:"?view=next"})),K("div",{class:V.dragbar}),K("div",{class:V.noteContainer},K("div",{class:V.noteWrapper}),K("div",{class:V.noteButtons},K("button",{class:V.noteButtonsSmaller,tabindex:"-1",title:"Smaller notes font size"},"Smaller notes font size"),K("button",{class:V.noteButtonsBigger,tabindex:"-1",title:"Bigger notes font size"},"Bigger notes font size"))),K("div",{class:V.infoContainer},K("div",{class:V.infoPage},K("button",{class:V.infoPagePrev,tabindex:"-1",title:"Previous"},"Previous"),K("span",{class:V.infoPageText}),K("button",{class:V.infoPageNext,tabindex:"-1",title:"Next"},"Next")),K("time",{class:V.infoTime,title:"Current time"}),K("time",{class:V.infoTimer,title:"Timer"})))),t})(e.parent)),(e=>{let t=!1;r(V.dragbar).addEventListener("mousedown",(()=>{t=!0,r(V.dragbar).classList.add("active")})),window.addEventListener("mouseup",(()=>{t=!1,r(V.dragbar).classList.remove("active")})),window.addEventListener("mousemove",(e=>{if(!t)return;const n=e.clientX/document.documentElement.clientWidth*100;r(V.container).style.setProperty("--bespoke-marp-presenter-split-ratio",`${Math.max(0,Math.min(100,n))}%`)})),r(V.nextContainer).addEventListener("click",(()=>e.next()));const n=r(V.next),o=(i=n,(e,t)=>{var n;return null===(n=i.contentWindow)||void 0===n?void 0:n.postMessage(`navigate:${e},${t}`,"null"===window.origin?"*":window.origin)});var i;n.addEventListener("load",(()=>{r(V.nextContainer).classList.add("active"),o(e.slide(),e.fragmentIndex),e.on("fragment",(({index:e,fragmentIndex:t})=>o(e,t)))}));const a=document.querySelectorAll(".bespoke-marp-note");a.forEach((e=>{e.addEventListener("keydown",(e=>e.stopPropagation())),r(V.noteWrapper).appendChild(e)})),e.on("activate",(()=>a.forEach((t=>t.classList.toggle("active",t.dataset.index==e.slide())))));let s=0;const l=e=>{s=Math.max(-5,s+e),r(V.noteContainer).style.setProperty("--bespoke-marp-note-font-scale",(1.2**s).toFixed(4))},c=()=>l(1),d=()=>l(-1),u=r(V.noteButtonsBigger),f=r(V.noteButtonsSmaller);u.addEventListener("click",(()=>{u.blur(),c()})),f.addEventListener("click",(()=>{f.blur(),d()})),document.addEventListener("keydown",(e=>{"+"===e.key&&c(),"-"===e.key&&d()}),!0),e.on("activate",(({index:t})=>{r(V.infoPageText).textContent=`${t+1} / ${e.slides.length}`}));const m=r(V.infoPagePrev),g=r(V.infoPageNext);m.addEventListener("click",(t=>{m.blur(),e.prev({fragment:!t.shiftKey})})),g.addEventListener("click",(t=>{g.blur(),e.next({fragment:!t.shiftKey})})),e.on("fragment",(({index:t,fragments:n,fragmentIndex:r})=>{m.disabled=0===t&&0===r,g.disabled=t===e.slides.length-1&&r===n.length-1}));let p=new Date;const v=()=>{const e=new Date,t=e=>`${Math.floor(e)}`.padStart(2,"0"),n=e.getTime()-p.getTime(),o=t(n/1e3%60),i=t(n/1e3/60%60),a=t(n/36e5%24);r(V.infoTime).textContent=e.toLocaleTimeString(),r(V.infoTimer).textContent=`${a}:${i}:${o}`};v(),setInterval(v,250),r(V.infoTimer).addEventListener("click",(()=>{p=new Date}))})(e)},X=e=>{if(!(e=>e.syncKey&&"string"==typeof e.syncKey)(e))throw new Error("The current instance of Bespoke.js is invalid for Marp bespoke presenter plugin.");Object.defineProperties(e,{openPresenterView:{enumerable:!0,value:H},presenterUrl:{enumerable:!0,get:R}}),g&&document.addEventListener("keydown",(t=>{"p"!==t.key||t.altKey||t.ctrlKey||t.metaKey||(t.preventDefault(),e.openPresenterView())}))};function H(){const{max:e,floor:t}=Math,n=e(t(.85*window.innerWidth),640),r=e(t(.85*window.innerHeight),360);return window.open(this.presenterUrl,F+this.syncKey,`width=${n},height=${r},menubar=no,toolbar=no`)}function R(){const e=new URLSearchParams(location.search);return e.set("view","presenter"),e.set("sync",this.syncKey),d(e)}const W=e=>{const t=u();return t===a&&e.appendChild(document.createElement("span")),{"":X,[i]:U,[a]:O}[t]},J=e=>{e.on("activate",(t=>{document.querySelectorAll(".bespoke-progress-parent > .bespoke-progress-bar").forEach((n=>{n.style.flexBasis=100*t.index/(e.slides.length-1)+"%"}))}))},Y=e=>{const t=Number.parseInt(e,10);return Number.isNaN(t)?null:t},z=(e={})=>{const t={history:!0,...e};return e=>{let n=!0;const r=e=>{const t=n;try{return n=!0,e()}finally{n=t}},o=(t={fragment:!0})=>{let n=t.fragment?Y(f("f")||""):null;((t,n)=>{const{min:r,max:o}=Math,{fragments:i,slides:a}=e,s=o(0,r(t,a.length-1)),l=o(0,r(n||0,i[s].length-1));s===e.slide()&&l===e.fragmentIndex||e.slide(s,{fragment:l})})((()=>{var t,r;if(location.hash){const[o]=location.hash.slice(1).split(":~:");if(/^\d+$/.test(o))return(null!==(t=Y(o))&&void 0!==t?t:1)-1;const i=document.getElementById(o)||document.querySelector(`a[name="${CSS.escape(o)}"]`);if(i){const{length:t}=e.slides;for(let o=0;o<t;o+=1)if(e.slides[o].contains(i)){const t=null===(r=e.fragments)||void 0===r?void 0:r[o],a=i.closest("[data-marpit-fragment]");if(t&&a){const e=t.indexOf(a);e>=0&&(n=e)}return o}}}return 0})(),n)};e.on("fragment",(({index:e,fragmentIndex:r})=>{n||m({f:0===r||r.toString()},{location:{...location,hash:`#${e+1}`},setter:(...e)=>t.history?history.pushState(...e):history.replaceState(...e)})})),setTimeout((()=>{o(),window.addEventListener("hashchange",(()=>r((()=>{o({fragment:!1}),m({f:void 0})})))),window.addEventListener("popstate",(()=>{n||r((()=>o()))})),n=!1}),0)}},G=(e={})=>{var t;const n=e.key||(null===(t=window.history.state)||void 0===t?void 0:t.marpBespokeSyncKey)||Math.random().toString(36).slice(2),r=`bespoke-marp-sync-${n}`;var i;i={marpBespokeSyncKey:n},m({},{setter:(e,...t)=>o({...e,...i},...t)});const a=()=>{const e=p(r);return e?JSON.parse(e):Object.create(null)},s=e=>{const t=a(),n={...t,...e(t)};return v(r,JSON.stringify(n)),n},l=()=>{window.removeEventListener("pageshow",l),s((e=>({reference:(e.reference||0)+1})))};return e=>{l(),Object.defineProperty(e,"syncKey",{value:n,enumerable:!0});let t=!0;setTimeout((()=>{e.on("fragment",(e=>{t&&s((()=>({index:e.index,fragmentIndex:e.fragmentIndex})))}))}),0),window.addEventListener("storage",(n=>{if(n.key===r&&n.oldValue&&n.newValue){const r=JSON.parse(n.oldValue),o=JSON.parse(n.newValue);if(r.index!==o.index||r.fragmentIndex!==o.fragmentIndex)try{t=!1,e.slide(o.index,{fragment:o.fragmentIndex,forSync:!0})}finally{t=!0}}}));const o=()=>{const{reference:e}=a();void 0===e||e<=1?h(r):s((()=>({reference:e-1})))};window.addEventListener("pagehide",(e=>{e.persisted&&window.addEventListener("pageshow",l),o()})),e.on("destroy",o)}},{PI:Q,abs:Z,sqrt:ee,atan2:te}=Math,ne={passive:!0},re=({slope:e=-.7,swipeThreshold:t=30}={})=>n=>{let r;const o=n.parent,i=e=>{const t=o.getBoundingClientRect();return{x:e.pageX-(t.left+t.right)/2,y:e.pageY-(t.top+t.bottom)/2}};o.addEventListener("touchstart",(({touches:e})=>{r=1===e.length?i(e[0]):void 0}),ne),o.addEventListener("touchmove",(e=>{if(r)if(1===e.touches.length){e.preventDefault();const t=i(e.touches[0]),n=t.x-r.x,o=t.y-r.y;r.delta=ee(Z(n)**2+Z(o)**2),r.radian=te(n,o)}else r=void 0})),o.addEventListener("touchend",(o=>{if(r){if(r.delta&&r.delta>=t&&r.radian){const t=(r.radian-e+Q)%(2*Q)-Q;n[t<0?"next":"prev"](),o.stopPropagation()}r=void 0}}),ne)},oe=new Map;oe.clear(),oe.set("none",{backward:{both:void 0,incoming:void 0,outgoing:void 0},forward:{both:void 0,incoming:void 0,outgoing:void 0}});const ie={both:"",outgoing:"outgoing-",incoming:"incoming-"},ae={forward:"",backward:"-backward"},se=e=>`--marp-bespoke-transition-animation-${e}`,le=e=>`--marp-transition-${e}`,ce=se("name"),de=se("duration"),ue=e=>new Promise((t=>{const n={},r=document.createElement("div"),o=e=>{r.remove(),t(e)};r.addEventListener("animationstart",(()=>o(n))),Object.assign(r.style,{animationName:e,animationDuration:"1s",animationFillMode:"both",animationPlayState:"paused",position:"absolute",pointerEvents:"none"}),document.body.appendChild(r);const i=getComputedStyle(r).getPropertyValue(le("duration"));i&&(n.defaultDuration=i),((e,t)=>{requestAnimationFrame((()=>{e.style.animationPlayState="running",requestAnimationFrame((()=>t(void 0)))}))})(r,o)})),fe=async e=>oe.has(e)?oe.get(e):(e=>{const t={},n=[];for(const[r,o]of Object.entries(ie))for(const[i,a]of Object.entries(ae)){const s=`marp-${o}transition${a}-${e}`;n.push(ue(s).then((e=>{t[i]=t[i]||{},t[i][r]=e?{...e,name:s}:void 0})))}return Promise.all(n).then((()=>t))})(e).then((t=>(oe.set(e,t),t))),me=e=>Object.values(e).flatMap(Object.values).every((e=>!e)),ge=(e,{type:t,backward:n})=>{const r=e[n?"backward":"forward"],o=(()=>{const e=r[t],n=e=>({[ce]:e.name});if(e)return n(e);if(r.both){const e=n(r.both);return"incoming"===t&&(e[se("direction")]="reverse"),e}})();return!o&&n?ge(e,{type:t,backward:!1}):o||{[ce]:"__bespoke_marp_transition_no_animation__"}},pe=e=>{if(e)try{const t=JSON.parse(e);if((e=>{if("object"!=typeof e)return!1;const t=e;return"string"==typeof t.name&&(void 0===t.duration||"string"==typeof t.duration)})(t))return t}catch(e){}},ve="_tSId",he="_tA",ye="bespoke-marp-transition-warming-up",be=window.matchMedia("(prefers-reduced-motion: reduce)"),we="__bespoke_marp_transition_reduced_outgoing__",xe="__bespoke_marp_transition_reduced_incoming__",ke={forward:{both:void 0,incoming:{name:xe},outgoing:{name:we}},backward:{both:void 0,incoming:{name:xe},outgoing:{name:we}}},$e=e=>{if(!document.startViewTransition)return;const t=t=>(void 0!==t&&(e._tD=t),e._tD);let n;t(!1),((...e)=>{const t=[...new Set(e).values()];return Promise.all(t.map((e=>fe(e)))).then()})(...Array.from(document.querySelectorAll("section[data-transition], section[data-transition-back]")).flatMap((e=>[e.dataset.transition,e.dataset.transitionBack].flatMap((e=>{const t=pe(e);return[null==t?void 0:t.name,(null==t?void 0:t.builtinFallback)?`__builtin__${t.name}`:void 0]})).filter((e=>!!e))))).then((()=>{document.querySelectorAll("style").forEach((e=>{e.innerHTML=e.innerHTML.replace(/--marp-transition-duration:[^;}]*[;}]/g,(e=>e.slice(0,-1)+"!important"+e.slice(-1)))}))}));const r=(n,{back:r,cond:o})=>i=>{var a;const s=t();if(s)return!!i[he]||!("object"!=typeof s||(s.skipTransition(),!i.forSync));if(!o(i))return!0;const l=e.slides[e.slide()],c=()=>{var e;return null!==(e=i.back)&&void 0!==e?e:r},d="data-transition"+(c()?"-back":""),u=l.querySelector(`section[${d}]`);if(!u)return!0;const f=pe(null!==(a=u.getAttribute(d))&&void 0!==a?a:void 0);return!f||((async(e,{builtinFallback:t=!0}={})=>{let n=await fe(e);if(me(n)){if(!t)return;return n=await fe(`__builtin__${e}`),me(n)?void 0:n}return n})(f.name,{builtinFallback:f.builtinFallback}).then((e=>{if(!e){t(!0);try{n(i)}finally{t(!1)}return}let r=e;be.matches&&(console.warn("Use a constant animation to transition because preferring reduced motion by viewer has detected."),r=ke);const o=document.getElementById(ve);o&&o.remove();const a=document.createElement("style");a.id=ve,document.head.appendChild(a),((e,t)=>{const n=[`:root{${le("direction")}:${t.backward?-1:1};}`,":root:has(.bespoke-marp-inactive){cursor:none;}"],r=t=>{var n,o,i;const a=(null===(n=e[t].both)||void 0===n?void 0:n.defaultDuration)||(null===(o=e[t].outgoing)||void 0===o?void 0:o.defaultDuration)||(null===(i=e[t].incoming)||void 0===i?void 0:i.defaultDuration);return"forward"===t?a:a||r("forward")},o=t.duration||r(t.backward?"backward":"forward");void 0!==o&&n.push(`::view-transition-group(*){${de}:${o};}`);const i=e=>Object.entries(e).map((([e,t])=>`${e}:${t};`)).join("");return n.push(`::view-transition-old(root){${i(ge(e,{...t,type:"outgoing"}))}}`,`::view-transition-new(root){${i(ge(e,{...t,type:"incoming"}))}}`),n})(r,{backward:c(),duration:f.duration}).forEach((e=>{var t;return null===(t=a.sheet)||void 0===t?void 0:t.insertRule(e)}));const s=document.documentElement.classList;s.add(ye);let l=!1;const d=()=>{l||(n(i),l=!0,s.remove(ye))},u=()=>{t(!1),a.remove(),s.remove(ye)};try{t(!0);const e=document.startViewTransition(d);t(e),e.finished.finally(u)}catch(e){console.error(e),d(),u()}})),!1)};e.on("prev",r((t=>e.prev({...t,[he]:!0})),{back:!0,cond:e=>{var t;return e.index>0&&!((null===(t=e.fragment)||void 0===t||t)&&n.fragmentIndex>0)}})),e.on("next",r((t=>e.next({...t,[he]:!0})),{cond:t=>t.index+1<e.slides.length&&!(n.fragmentIndex+1<n.fragments.length)})),setTimeout((()=>{e.on("slide",r((t=>e.slide(t.index,{...t,[he]:!0})),{cond:t=>{const n=e.slide();return t.index!==n&&(t.back=t.index<n,!0)}}))}),0),e.on("fragment",(e=>{n=e}))};let Ee;const Le=()=>(void 0===Ee&&(Ee="wakeLock"in navigator&&navigator.wakeLock),Ee),Se=async()=>{const e=Le();if(e)try{return await e.request("screen")}catch(e){console.warn(e)}return null},Pe=async()=>{if(!Le())return;let e;const t=()=>{e&&"visible"===document.visibilityState&&Se()};for(const e of["visibilitychange","fullscreenchange"])document.addEventListener(e,t);return e=await Se(),e};((e=document.getElementById(":$p"))=>{(()=>{const e=f("view");r.dataset.bespokeView=e===a||e===i?e:""})();const t=(e=>{const t=f(e);return m({[e]:void 0}),t})("sync")||void 0;n.from(e,((...e)=>{const t=s.findIndex((e=>u()===e));return e.map((([e,n])=>e[t]&&n)).filter((e=>e))})([[1,1,0],G({key:t})],[[1,1,1],W(e)],[[1,1,0],_],[[1,1,1],b],[[1,0,0],S()],[[1,1,1],T],[[1,1,1],z({history:!1})],[[1,1,0],I()],[[1,1,0],E],[[1,0,0],J],[[1,1,0],re()],[[1,0,0],M()],[[1,0,0],$e],[[1,1,1],w],[[1,1,0],Pe]))})()}();</script></body></html>